

106 13482
10/9/03

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/44153 A1

(51) International Patent Classification⁷: **C07D 213/85**,
A61K 31/44, A61P 29/00, C07D 405/12, 401/12, 401/10,
213/73, 213/80, 213/82, 498/04, A61K 31/4545, 31/496,
31/5377

(21) International Application Number: PCT/EP01/13338

(22) International Filing Date:
19 November 2001 (19.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2000-366708 1 December 2000 (01.12.2000) JP

(71) Applicant (for all designated States except US): **BAYER AKTIENGESELLSCHAFT** [DE/DE]; 51368 Leverkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **MURATA, Toshiki** [JP/JP]; 1-3-501, Nakano-cho, Ikoma-shi, Nara 630-0267 (JP). **SAKAKIBARA, Sachiko** [JP/JP]; 544-1A-1, Sanjo-cho, Nara-shi, Nara 630-8244 (JP). **YOSHINO, Takashi** [JP/JP]; 1-1-17-101, Saidaiji-Nogami-cho, Nara-shi, Nara 631-0833 (JP). **IKEGAMI, Yuka** [JP/JP]; 942, Fushimi Godo Shukusha, Nishibugyo-cho, Fushimi-ku, Kyoto 612-8104 (JP). **MA-SUDA, Tsutomu** [JP/JP]; 3-15-6-6A, Jingu, Nara-shi, Nara 631-0804 (JP). **SHIMADA, Mitsuyuki** [JP/DE]; Mozartstr. 31, 40667 Meerbusch (DE). **SHINTANI, Takuya** [JP/JP]; 4-24-1, Seikadai, Seika-cho, Soraku-gun, Kyoto 619-0238 (JP). **SHIMAZAKI, Makoto** [JP/JP]; 5-5-3-1, Kunimidai, Kizu-cho, Soraku-gun, Kyoto 619-0216 (JP). **LOWINGER, Timothy, B.** [CA/JP]; 5-7-203, Chitose-cho, Nishinomiya-shi, Hyogo

662-0046 (JP). **ZIEGELBAUER, Karl, B.** [DE/DE]; Guttentag-Loben-Str. 21, 42781 Haan (DE). **FUCHIKAMI, Kinji** [JP/JP]; 7-1-8-A103, Umemidai, Kizu-cho, Soraku-gun, Kyoto 619-0215 (JP). **UMEDA, Masaomi** [JP/JP]; 2-840-156, Sahodai, Nara-shi, Nara 630-8105 (JP). **KOMURA, Hiroshi** [JP/JP]; 2-1-8, Saidaiji-Shiba-machi, Nara-shi, Nara 631-0825 (JP). **YOSHIDA, Nagahiro** [JP/JP]; 5-18-15, Saganakadai, Kizu-cho, Soraku-gun, Kyoto 619-0223 (JP).

(74) Common Representative: **BAYER AKTIENGESELLSCHAFT**; 51368 Leverkusen (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: 4-ARYL PYRIDINE DERIVATIVES

(57) Abstract: 4-aryl pyrimidine compounds of general formula and salts thereof; wherein X is CH or N; R1 is hydrogen, halogen, C1-6 alkyl, C1-6 alkoxy, etc.; R2 is hydrogen or hydroxy; R3 is hydrogen, C1-6 alkyl, etc.; R4 is hydrogen, hydroxy, halogen, amino, etc.; R5 is hydroxy, amino, carboxy, etc.; R6 is hydrogen, carbamoyl, cyano, carboxy, C1-6 alkoxy, carbonyl, etc. and R7 is amino or C1-6 alkanoylamino. The compounds (I) or the salts thereof have an excellent anti-inflammatory activity and the like.

WO 02/44153 A1

4-ARYL PYRIDINE DERIVATIVES

DETAILED DESCRIPTION OF INVENTION

5 TECHNICAL FIELD

The present invention relates to novel 4-aryl pyridine derivatives, processes for preparing them and pharmaceutical preparations containing them. The 4-aryl pyridine derivatives of the present invention inhibit I κ B kinase β (IKK- β or IKK-beta) activity, thus inhibit nuclear factor kappa B (NF- κ B) activity, and can be used for the prophylaxis and treatment of diseases associated with NF- κ B activity, in particular for the treatment of inflammatory diseases.

BACKGROUND ART

15

Nuclear factor kappa B (NF- κ B) belongs to a family of closely related homo- and hetero- dimeric transcription factor complexes composed of various combinations of the Rel/NF- κ B family of polypeptides. NF- κ B and related family members are involved in the regulation of more than 50 genes relating to immune and inflammatory responses ((Barnes PJ, Karin M (1997) N Engl J Med 336, 1066-1071) and (Baeuerle PA, Baichwal VR (1997) Adv Immunol 65, 111-137)). In most cell types, NF- κ B is present as a heterodimer comprising a 50 kDa and a 65 kDa subunit (p50/RelA). The heterodimer is sequestered in the cytoplasm in association with inhibitor of NF- κ B (I κ B)-family of proteins to be kept in an inactive state. I κ B-family proteins mask the nuclear translocation signal of NF- κ B. Upon stimulation of cells with various cytokines (e.g. TNF- α , IL-1), CD40 ligand, lipopolysaccharide (LPS), oxidants, mitogens (e.g. phorbol ester), viruses or many others. I κ B proteins are phosphorylated at specific serine residues, poly-ubiquitinated, and then degraded through a proteasome-dependent pathway. Freed from I κ B, the active NF- κ B is able to translocate to the nucleus where it binds in a selective manner to preferred gene-specific enhancer sequences. Among the genes being regulated by NF- κ B are many

30

coding for pro-inflammatory mediators, cytokines, cell adhesion molecules, and acute phase proteins. Expression of several of these cytokines and mediators in turn can lead to further activation of NF- κ B via autocrine and paracrine mechanisms.

5 Broad evidence is available that suggests a central role of NF- κ B in many inflammatory disorders including airway inflammation and asthma ((Yang L et al., J Exp Med 188 (1998), 1739-1750), (Hart LA et al. Am J Respir Crit Care Med 158 (1998), 1585-1592), (Stacey MA et al., Biochem Biophys Res Commun 236 (1997), 522-526) (Barnes P and Adcock IM, Trends Pharmacol Sci 18 (1997), 46-50)).

10

Further, it has been shown that glucocorticoids, which are by far the most effective treatment for asthma, inhibit airway inflammation by directly interacting with and inhibiting the activity of the transcription factors NF- κ B and activating peptide-1 (AP-1) ((Barnes P (1997) Pulmon Pharmacol Therapeut 10, 3-19) and (Dumont A et al. (1998) Trends Biochem Sci 23, 233-235)).

15

In general, inhibition of NF- κ B activation results in strong anti-inflammatory effects similar or superior to those brought upon by steroids. Consequently, NF- κ B inhibition should improve inflammatory symptoms typical for asthma; allergic
20 rhinitis; atopic dermatitis; hives; conjunctivitis; vernal catarrh; rheumatoid arthritis; systemic lupus erythematosus; psoriasis; idiopathic colitis; systemic inflammatory response syndrome; sepsis; polymyositis; dermatomyositis; Polyarthritis nodosa; mixed connective tissue disease; Sjogren's syndrome; gout, and the like.

20

25 Further, several studies imply that NF- κ B plays an essential role in neoplastic transformation. For example, NF- κ B is associated with cell transformation in vitro and in vivo as a result of gene overexpression, amplification, rearrangement, or translocation (Mercurio, F., and Manning, A.M. (1999) Oncogene, 18:6163-6171). In certain human lymphoid tumor cells, the genes of NF- κ B family members are
30 rearranged or amplified. Its possible involvement in cancer pathology is also disclosed in Mayo, M.W., Baldwin A.S. (2000) Biochimica et Biophysica Acta 1470

M55-M62. Mayo M.W. et al., discloses the inhibition of NF- κ B results in the blockage the initiation and/or progression of certain cancer, particularly colorectal cancer.

5 Finally, NF- κ B may also be involved in the regulation of neuronal cell death. It has been shown that NF- κ B becomes activated and promotes cell death in focal cerebral ischemia (Nature medicine Vol. 5 No. 5, May 1999).


10 Extensive research during the past years led to the identification of an I κ B kinase (IKK) complex as being responsible for the signal-induced I κ B phosphorylation (Hatada, E.N, et al. (2000) Current Opinion in Immunology, 12:52-58)). This complex is most likely the site of integration of all of the different stimuli leading to NF- κ B activation. The IKK-complex (molecular weight 700 – 900 kDa) is composed of various proteins including two homologous I κ B kinases, called IKK- α and IKK- β , an upstream kinase, NIK which induces NF- κ B, a scaffold protein called IKAP, 15 which tethers together the three kinases, and a regulatory subunit IKK- γ , which preferentially interacts with IKK- β .

20 IKK- β is a 756 amino acid serine-threonine kinase showing 52 % identity to and the same domain structure as IKK- α ((Mercurio F *et al.* (1997) Science 278, 860-866.), (Woronicz JD *et al.* (1997) Science 278, 866-869.), (Zandi E *et al.* (1997) Cell 91, 243-252.). IKK- β forms homo-dimers and hetero-dimers with IKK- α *in vitro* and in cells, respectively. IKK- β also interacts with IKK- γ , IKAP, NIK and I κ B α . Recombinant IKK- β phosphorylates I κ B α and I κ B β at specific serine residues with 25 equal efficacy (Li J *et al.* (1998) J Biol Chem 273, 30736-30741). IKK- β shows a higher constitutive kinase activity as compared to IKK- α . This is in agreement with data suggesting that over-expression of IKK- β activates the transcription of a NF- κ B-dependent reporter gene with a higher efficacy as compared to IKK- α . IKK- β has been shown to be activated in various cell lines or fresh human cells in response to 30 various stimuli including TNF- α , IL-1 β , LPS, anti-CD3/anti-CD28 co-stimulation,

protein kinase C and calcineurin, B-cell receptor/CD40 ligand stimulation, and vanadate. IKK- β is activated in fibroblast-like synoviocytes (FLS) isolated from the synovium of patients suffering from rheumatoid arthritis or osteoarthritis (Kempiak SJ *et al.* (1999) J Immunol 162, 3176-3187.). Furthermore, IKK- β can be activated
5 by the structurally related upstream kinases MEKK-1 and NIK, most likely through phosphorylation of specific serine residues within the T-loop (activation loop) and by certain protein kinase C isoforms (Lallena MJ *et al.* (1999) Mol Cell Biol 19, 2180-2188.). A catalytically inactive mutant of IKK- β has been shown to inhibit activation of NF- κ B by TNF- α , IL-1 β , LPS, anti-CD3/anti-CD28 stimulation
10 (Woronicz JD *et al.* (1997) Science 278, 866-869). The same effects are observed when MEKK1 or NIK are overexpressed. Additionally, IKK- β mutations in the activation loop inhibited IL-1 and TNF- α signaling (Delhase M *et al.* (1999) Science 284, 309-313.). Based on the experimental results described above, there is clear-cut evidence for a pivotal involvement of IKK- β in various pathways leading to NF- κ B
15 activation.

In summary, the specific inhibition of IKK- β should result in a strong anti-inflammatory and immuno-modulatory effect *in vivo* with the potential of improving the underlying causes of asthma and other diseases. In addition, anti-tumor and anti-
20 ischemic effects of an IKK- inhibitor may be expected.

Manna et al., disclose 4,6-disubstituted 3-cyano-2-aminopyridines represented by general formulas:




wherein

(R', R'') represent (OCH₃, OCH₃), (Cl, Cl), (H, Cl), (H, Br), (H, CH₃), (H, OCH₃),
(H, NO₂), or (H, N(CH₃)₂),

5

and



as a general anti-inflammatory, analgesic, and antipyretic agent (Eur J. Med. Chem.
34, 245-254(1999)).

10

However, the development of a novel compound having effective anti-inflammatory
actions based on a specific and selective inhibitory activity to NF- κ B has been still
desired.

15


SUMMARY OF THE INVENTION

20

As a result of extensive studies on chemical modification of pyridine derivatives, the
present inventors have found that the compounds of novel chemical structure related
to the present invention have unexpectedly excellent NF- κ B inhibitory activity based
on IKK- β inhibition and cytokine inhibition. The present invention has been
accomplished based on these findings.

This invention is to provide a novel 4-aryl pyridine derivatives shown by the
following formula (I) and salts thereof.

- 6 -



wherein

X is CH or N;

R¹ is hydrogen, hydroxy, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, nitro, amino, mono or di (C₁₋₆ alkyl)amino, phenylsulfonylamino, -NHR¹¹ or -O-(CH₂)_n-R¹²,

wherein

R¹¹ is phenyl substituted C₁₋₆ alkyl, C₁₋₆ alkanoyl or C₁₋₆alkylsulfonyl,

n represents an integer selected from 0 to 6, and

R¹² is C₂₋₆ alkenyl, benzoyl, mono or di phenyl, mono or di (C₁₋₆ alkyl)amino, C₁₋₆ alkanoyl, C₁₋₆ alkoxycarbonyl, or a 3 to 10 membered saturated or unsaturated ring having 0 to 3 heteroatoms selected from the group consisting of S, O and N, and said ring is optionally substituted by hydroxy, nitro, cyano, mono or di halogen, C₁₋₆ alkyl, halogen substituted C₁₋₆ alkyl, amino, mono or di (C₁₋₆ alkyl)amino, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, or phenyl;

R² is hydrogen, hydroxy, halogen, or C₁₋₆ alkyl;

5 R^3 is hydrogen, hydroxy, halogen, C_{1-6} alkoxy, C_{3-6} cycloalkyl substituted C_{1-6} alkyloxy, $-N R^{31}R^{32}$, or a 3 to 6 membered saturated ring having 0 to 3 heteroatoms selected from the group consisting of O and N, and said ring is optionally substituted by R^{33} ;

Wherein

10 R^{31} is hydrogen or C_{1-6} alkyl

R^{32} is hydrogen, C_{1-6} alkanoyl, or C_{1-6} alkyl optionally substituted by hydroxy or phenyl,

15 R^{33} is nitro, cyano, C_{1-6} alkyl optionally substituted by hydroxy or amino, C_{1-6} alkoxy, hydroxy substituted C_{1-6} alkyloxy, amino substituted C_{1-6} alkyloxy, C_{1-6} alkanoyl, carbamoyl or $-NR^{33a}R^{33b}$

Wherein

20 R^{33a} is hydrogen or C_{1-6} alkyl

R^{33b} is hydrogen, C_{1-6} alkyl optionally substituted by hydroxy or phenyl, C_{1-6} alkanoyl, C_{1-6} alkylsulfonyl, or trifluoroacetyl,

25 R^4 is hydrogen, hydroxy, carboxy, $-CO-NHR^{41}$, amino, C_{1-6} alkylsulfonylamino, or $-NH-COR^{41}$, C_{1-6} alkyl optionally substituted by R^{42} , C_{1-6} alkoxy, $R^{43}C_{1-6}$ alkyloxy,

wherein

30

R^{41} is C_{1-6} alkyl optionally substituted by R^{41a} , C_{1-6} alkoxy, oxo-tetrahydrofuryl, oxopyrrolidinyl, $-CH(OH)R^{41b}$, $-CH(NH_2)R^{41c}$, $-NHR^{41c}$, or piperazino optionally substituted by R^{41d} ,

5 wherein

R^{41a} is carboxy, C_{1-6} alkoxy, $-CH(NH_2)carboxy$, $-NR^{41a-1}R^{41a-2}$, or a
3 to 10 membered saturated ring having 0 to 3 heteroatoms
selected from the group consisting of O and N, and said ring is
10 optionally substituted by carboxy, C_{1-6} alkyl optionally
substituted by hydroxy or benzodioxane, C_{3-6} cycloalkyl, C_{1-6}
alkanoyl, carboxy, benzyl, C_{1-6} alkoxycarbonyl, or furoyl,

 wherein

15 R^{41a-1} is hydrogen or C_{1-6} alkyl optionally substituted by
hydroxy, C_{1-6} alkyloxy, C_{3-8} cycloalkyl, or piperidino,

R^{41a-2} is hydrogen or C_{1-6} alkyl optionally substituted by
20 hydroxy, C_{1-6} alkyloxy or C_{3-6} cycloalkyl, C_{1-6} alkoxy or
a 3 to 6 membered saturated ring having 0 to 3
heteroatoms selected from the group consisting of O
and N, and said ring is optionally substituted by
carboxy, C_{1-6} alkyl, C_{1-6} alkanoyl, or C_{1-6} alkyloxy,

25 R^{41b} is C_{1-6} alkyl optionally substituted by carboxy or C_{1-6} alkyloxy,
 C_{1-6} alkoxy, or C_{1-6} alkoxycarbonyl,

R^{41c} is carboxy, C_{1-6} alkyl optionally substituted by carboxy or a 3
30 to 6 membered saturated ring having 0 to 3 heteroatoms
selected from the group consisting of O and N,

or

5 R^{41d} is C_{1-6} alkyl optionally substituted by carboxy or C_{1-6} alkyloxy,
or C_{1-6} alkoxy

10 R^{42} is C_{1-6} alkoxy, carboxy, amino, $-CH(NH_2)$ -carboxy or a 5 to 7
membered saturated or unsaturated ring having 0 to 3 heteroatoms
selected from the group consisting of O and N, and said ring is
optionally substituted by hydroxy, nitro, mono or di halogen, C_{1-6}
alkyl, halogen substituted C_{1-6} alkyl, amino, mono or di (C_{1-6}
alkyl)amino, or carbamoyl;

15 R^{43} is carboxy, amino, $-CH(NH_2)$ -carboxy or a 5 to 7 membered saturated
or unsaturated ring having 0 to 3 heteroatoms selected from the group
consisting of O and N, and said ring is optionally substituted by
hydroxy, nitro, mono or di halogen, C_{1-6} alkyl, halogen substituted
 C_{1-6} alkyl, amino, mono or di (C_{1-6} alkyl)amino, or carbamoyl;

20 or

25 R^3 and R^4 may form, together with the carbon atoms in the benzene ring, a 4 to 6
membered saturated ring having 0 to 3 heteroatoms selected from the group
consisting of O and N, and said ring is optionally substituted by one or more
substituents selected from the group consisting of hydroxy, nitro, mono or di
halogen, C_{1-6} alkyl, halogen substituted C_{1-6} alkyl, oxo, amino, mono or di
(C_{1-6} alkyl)amino, and carbamoyl;

30 R^5 is hydrogen, cyano, carboxy, carbamoyl, C_{1-6} alkyl optionally substituted by
hydroxy or carbamoyl, and C_{1-6} alkoxycarbonyl, and

- 10 -

R^6 is $-NR^{61}R^{62}$,

wherein

5 R^{61} is hydrogen or C_{1-6} alkyl,

R^{62} is hydrogen, C_{1-6} alkyl, phenyl, benzyl, C_{1-6} alkanoyl, or

10 $NR^{61}R^{62}$ may form, together with the nitrogen atom to which they are attached, a saturated 5-6 membered ring optionally containing NH or O as other heteroatoms than the adjacent N atom

or

15 R^5 and R^6 may form, together with the carbon atoms in the pyridine ring, a 5 to 7 membered saturated or unsaturated ring having 0 to 3 heteroatoms selected from the group consisting of O, S and N, and said ring optionally having substituents selected from the group consisting of halogen, nitro, cyano, oxo, thioxo, C_{1-6} alkyl, C_{1-6} alkylsulfonyl, C_{1-6} alkoxy, C_{1-6} alkoxycarbonyl, 20 phenyl, C_{1-6} alkanoyl, amino, C_{1-6} alkylamino, C_{1-6} alkanoylamino, carbamoyl, C_{3-8} cycloalkylaminocarbonyl, C_{1-6} alkylaminocarbonyl, halogen substituted C_{1-6} alkylaminocarbonyl, di (C_{1-6} alkyl)aminocarbonyl, benzoyl-amino, phenylsulfonyl, di(C_{1-6} alkyl)amino C_{1-6} alkylaminocarbonyl, hydroindenylaminocarbonyl, diphenylmethylaminocarbonyl, pyrrolidino- 25 carbonyl, C_{1-6} alkyloxy C_{1-6} alkyl amino carbonyl, morpholinocarbonyl, piperazinocarbonyl, phenyl C_{1-6} alkylaminocarbonyl, carboxy C_{1-6} alkylamino-carbonyl, C_{3-8} cycloalkyl C_{1-6} alkylaminocarbonyl, hydroxy C_{1-6} alkylamino-carbonyl, and methylsulfonylaminocarbonyl

30 or a salt thereof.

5 The compounds of the present invention surprisingly show excellent IKK- β kinase inhibitory activity and cytokine inhibitory activity. They are, therefore suitable especially as NF- κ B inhibitors and in particular for the production of pharmaceuticals or pharmaceutical compositions, which may be useful to treat NF- κ B dependent diseases.

10 More specifically, since the 4-aryl pyridine derivatives of the present invention inhibit IKK- β kinase activity, they are useful for treatment and prophylaxis of diseases involving NF- κ B activity as follows: inflammatory symptoms including asthma; allergic rhinitis; atopic dermatitis; hives; conjunctivitis; vernal catarrh; chronic arthrorheumatism; systemic lupus erythematosus; psoriasis; diabrotic colitis; systemic inflammatory response syndrome (SIRS); sepsis; polymyositis; dermatomyositis (DM); polyarthritis nodosa (PN); mixed connective tissue disease (MCTD); Sjogren's syndrome; gout; and the like.

15 The compounds of the present invention are also useful for treatment and prophylaxis of diseases like ischemia and tumor, since the diseases also relate to IKK- β kinase and NF- κ B activity.

20 Preferred compounds of the formula (I) are those wherein:

X is CH or N;

25 R¹ is hydrogen, halogen, C₁₋₆ alkoxy, or cyclopropyl methoxy;

R² is hydrogen;

30 R³ is hydrogen, hydroxy, halogen, amino, mono or di(C₁₋₆ alkyl)amino, acetamido, C₁₋₆alkoxy, cyclopropyl methoxy, C₁₋₆ alkyl(hydroxy substituted C₁₋₆ alkyl)amino, C₁₋₆ alkyl(benzyl)amino, morpholino, piperidino, or

pyrrolidino optionally substituted by C₁₋₆ alkyl, hydroxy substituted C₁₋₆ alkyl, amino, di (C₁₋₆ alkyl)amino, or trifluoroacetyl amino;

5 R⁴ is hydrogen, hydroxy, carboxy, amino, C₁₋₆ alkylsulfonylamino, piperazino, C₁₋₆ alkyl substituted piperazino, piperidino substituted C₁₋₆ alkyloxy, piperidino C₁₋₆ alkyl- aminocarbonyl, or -NH-COR⁴¹,

wherein

10 R⁴¹ is C₁₋₆ alkyl optionally substituted by R^{41a}, C₁₋₆ alkoxy, oxotetrahydrofuryl, oxopyrrolidinyl, -CH(OH)R^{41b}, or -CH(NH₂)R^{41c},

wherein

15 R^{41a} is C₁₋₆ alkoxy, carboxy, -CH(NH₂)-carboxy, -NHR^{41a-1} (wherein R^{41a-1} is hydrogen, C₁₋₆ alkyl optionally substituted by hydroxy, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, or piperidino), -N(C₁₋₆ alkyl)R^{41a-2} (wherein R^{41a-2} is C₁₋₆ alkyl or C₁₋₆ alkyl substituted pyrrolidinyl), pyrrolidinyl, piperidino optionally substituted by carboxy or C₁₋₆ alkoxycarbonyl, piperidino fused with cyclohexane, or piperazino optionally substituted by C₁₋₆ alkyl, hydroxy substituted C₁₋₆ alkyl, benzodioxane substituted C₁₋₆ alkyl, benzyl, C₁₋₆ alkanoyl, cyclohexyl, or furoyl,

20 R^{41b} is C₁₋₆ alkyl optionally substituted by carboxy or C₁₋₆ alkoxycarbonyl,

 R^{41c} is C₁₋₆ alkyl optionally substituted by carboxy,

or

30

R³ and R⁴ may form -NR⁴⁰¹-CO-O-(wherein R⁴⁰¹ is hydrogen or C₁₋₆ alkyl);

R⁵ is hydrogen, carbamoyl, cyano, carboxy, or hydroxymethyl; and

R⁶ is amino or acetamido

5

or

R⁵ and R⁶ may form -R⁵⁰-CH₂-NH-, -R⁵⁰-CO-NH-, -R⁵⁰-SO₂-NH-, or -R⁵⁰-C(=S)-NH-

10

wherein

R⁵⁰ is -CHR⁵⁰¹-O-, -CH₂-N R⁵⁰¹-, -CO-NR⁵⁰¹-, (wherein R⁵⁰¹ is hydrogen, C₁₋₆ alkyl, C₁₋₆ alkanoyl, C₁₋₆ alkoxy carbonyl, carbamoyl, C₁₋₆ alkylsulfonyl, C₃₋₈ cycloalkylaminocarbonyl, C₁₋₆ alkylamino-carbonyl, di (C₁₋₆ alkyl)aminocarbonyl or phenyl)

15

or a salt thereof.

20 In the context of the present invention, the substituents, if not stated otherwise, in general have the following meaning:

C₁₋₆ alkyl in general represents a straight-chain or branched hydrocarbon radical having 1 to 6 carbon atoms. Non-limiting examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, pentyl, isopentyl, hexyl, isohexyl.

25

C₁₋₆ alkoxy in general represents a straight-chain or branched hydrocarbon radical having 1 to 6 carbon atoms and bound via an oxygen atom. Non-limiting examples include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, pentoxy, isopentoxy, hexoxy, isohexoxy.

30

C₃₋₈ cycloalkyl in general represents a cyclic hydrocarbon radical having 3 to 8 carbon atoms. Cyclopropyl, cyclopentyl and cyclohexyl are preferred. Non-limiting examples include cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

- 5 C₂₋₆ alkenyl stands for straight-chain or branched residues containing one or more double bonds, e.g. vinyl, allyl.

The preferable compounds of the present invention are as follows:

- 10 5-({3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl} amino)-4-hydroxy-5-oxopentanoate;
N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-5-oxotetrahydro-2-furancarboxamide;
N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}methane-sulfonamide;
15 N⁴-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-L-asparagine;
N¹-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-L-asparagine;
N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-(1-piperidinyl)-propanamide;
5-({4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl} amino)-4-
20 hydroxy-5-oxopentanoate;
4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-N-[2-(1-piperidinyl)ethyl]-benzamide;
4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]benzoic acid;
5-({5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-chlorophenyl} amino)-
25 4-hydroxy-5-oxopentanoate;
N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-2-[4-(2-furoyl)-1-piperazinyl]acetamide;
N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-(4-ethyl-1-piperazinyl)propanamide;
30 N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-octahydro-1(2H)-quinolinypropanamide;

N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^2 -cyclopentylglycinamide;

N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^2 -(cyclopropylmethyl)glycinamide;

5 N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^2 -propylglycinamide;

N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^2 -(3-hydroxypropyl)glycinamide;

10 N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^3 -(cyclopropylmethyl)- β -alaninamide;

N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^2,N^2 -dimethylglycinamide;

N -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-2-(1-pyrrolidinyl)acetamide;

15 N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^2 -[2-(methyloxy)ethyl]glycinamide;

N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(3-amino-1-pyrrolidinyl)phenyl]- β -alaninamide;

20 N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(1-piperidinyl)phenyl]- β -alaninamide;

N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(1-pyrrolidinyl)phenyl]- β -alaninamide;

N^1 -{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-[ethyl(2-hydroxyethyl)amino]phenyl}- β -alaninamide;

25 N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(4-morpholinyl)phenyl]- β -alaninamide;

N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(dimethylamino)phenyl]- β -alaninamide;

30 N -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-4-chlorophenyl}-3-(1-piperidinyl)propanamide;

2-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]benzoic acid;

- 2-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-N-[2-(1-piperidinyl)ethyl]-benzamide;
- N¹-{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-chlorophenyl}-N²-(cyclopropylmethyl)glycinamide;
- 5 N¹-{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-chlorophenyl}-N²-(2-methoxyethyl)glycinamide;
- N¹-{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-chlorophenyl}-β-alaninamide;
- 2-amino-4-(4-amino-3-hydroxyphenyl)-6-(2-hydroxyphenyl)nicotinonitrile;
- 10 N-{4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-hydroxyphenyl}-acetamide;
- N-{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-chlorophenyl}-3-(1-piperidinyl)propanamide;
- N¹-[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(dimethylamino)-phenyl]-N²-(cyclopropylmethyl)glycinamide;
- 15 N-[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(dimethylamino)phenyl]-3-(1-piperidinyl)propanamide;
- N¹-{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]phenyl}-L-leucinamide;
- 20 N¹-{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl}-N²-(cyclopropylmethyl)glycinamide;
- N¹-(5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-{3-[(trifluoroacetyl)-amino]-1-pyrrolidinyl}phenyl)-L-leucinamide;
- N-(5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-{3-[(trifluoroacetyl)-amino]-1-pyrrolidinyl}phenyl)-3-(1-piperidinyl)propanamide;
- 25 N¹-(5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-{3-[(trifluoroacetyl)-amino]-1-pyrrolidinyl}phenyl)-N²-(2-methoxyethyl)glycinamide;
- N¹-(5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-{3-[(trifluoroacetyl)amino]-1-pyrrolidinyl}phenyl)-N²-(cyclopropylmethyl)glycinamide;
- 30 2-amino-6-(2-hydroxyphenyl)-4-(3-hydroxyphenyl)nicotinonitrile;

N-{4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-[2-(1-piperidinyl)-ethoxy]phenyl}acetamide;

N-{4-[2-amino-3-(hydroxymethyl)-6-(2-hydroxyphenyl)-4-pyridinyl]-2-hydroxyphenyl}acetamide;

5 2-[6-amino-4-[4-(ethylamino)-3-hydroxyphenyl]-5-(hydroxymethyl)-2-pyridinyl]-3-(cyclopropylmethoxy)phenol;

N-{4-[2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-3-(hydroxymethyl)-4-pyridinyl]-2-hydroxyphenyl}acetamide;

10 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one;

and pharmaceutically acceptable salts thereof.


15 The compound of the formula (I) of the present invention can be, but not limited to be, prepared by combining various known methods. In some embodiments, one or more of the substituents, such as amino group, carboxy group, and hydroxy group of the compounds used as starting materials or intermediates are advantageously protected by a protecting group known to a person skilled in the art. Examples of the protecting groups are described in "Protective Groups in Organic Synthesis (2nd

20 Edition)" by Greene and Wuts.

The typical processes for preparing the compounds (I) of the present invention are explained below.

25 (1) The compound of the formula (I-a):


- 18 -




in which

X, R¹, R² and R³ are the same as defined above and R^{4a} is C₁₋₆ alkylsulfonyl, or
 5 -COR⁴¹ (R⁴¹ is the same as defined.),

can be prepared, for example, by the following reaction A.




10 In the step 1, the compound of the formula (II):



(wherein

5 R^1 , R^2 and X are the same as defined above), is reacted with an aldehyde of the formula (III):



(wherein

10 R^3 is the same as defined above), malononitrile, and ammonium acetate to prepare the compound (IV).

In step 2, the nitro group is reduced to convert to the amino group.

15 In step 3, the amino group is further modified to obtain a desired group (NHR^{4a}).

The substituents of the compound (II) or (III) are, if necessary, protected by an appropriate protecting group (e.g., benzyl, silyl) during the reaction, and deprotected afterward.

20

The step 1 is carried out without a solvent or in a solvent including, for instance, ethers, such as dioxane, and tetrahydrofuran; aromatic hydrocarbons such as benzene, toluene and xylene; nitriles such as acetonitrile; amides such as dimethylformamide (DMF) and dimethylacetamide; sulfoxides such as dimethyl sulfoxide, and others.

25

The reaction temperature is optionally set depending on the compounds to be reacted. The reaction temperature is usually about 50°C to 200°C. The reaction is conducted for, usually, 30 minutes to 48 hrs. and preferably 1 to 24 hrs.


- 20 -

The compounds of (II) and (III) can be commercially available, or can be prepared by the use of known techniques.

- 5 The step 2 is carried out in the presence of a reducing agent and a hydrogen donor at about room temperature to 120°C. The reaction time and the solvent used in the step 2 are similar as that used in the step 1.

10 The step 3 is carried out under the condition usually employed by a skilled person in the art to synthesize amides (NHR^{4a}).

(2) Alternatively, the compound of the formula (I-b):




15

wherein


X, R¹, R², R³ and R⁴¹ are the same as defined above, can be prepared, for example, by the following reaction B.

20

- 21 -



The compound (II) is reacted with an aldehyde of the formula (III'):



5 (wherein

R^3 is the same as defined above, and R^{4b} is amino or alkoxy),
malononitrile, and ammonium acetate to prepare the compound (IV'). R^{4b} is
further modified to obtain a desired group (OH or NHR^{41}).

10

The substituents of the compound of (II) or (III) are, if necessary, protected by an appropriate protecting group (e.g., benzyl, silyl) during the reaction, and deprotected afterward.


15

The step 1 of the reaction B can be carried out under the similar condition to that of reaction A.

The step 2 in the reaction B can be hydrolysis and can be carried out under the condition usually employed by a skilled person in the art.

5 The step 3 in the reaction B can be carried out under the condition usually employed by a skilled person in the art to synthesize amides (CONHR⁴¹).

(3) Alternatively, the compound of the formula (I-c):




10 wherein


X, R¹, R², R³ and R⁴ are the same as defined, and R^{5a} is carboxy, carbamoyl, C₁₋₆ alkoxy carbonyl, hydroxy C₁₋₆ alkyl, C₁₋₆ alkyl carbamoyl, or C₁₋₆ alkyl,

15 can be prepared, for example, by the following reaction C.

- 23 -



The compound (II) is reacted with an aldehyde of the formula (III''):



5 (wherein

R^3 and R^4 are the same defined above),

10 a nitrile of the formula, $t\text{Bu-OCO-CH}_2\text{CN}$, and ammonium acetate to prepare the compound (IV''). Then COOtBu of the resulting compound (IV'') can be modified to obtain a desired compound (R^{5a}).

The substituents of the compound of (II) or (III'') may be protected by an appropriate protecting group (e.g., benzyl, silyl) during the reaction, and deprotected afterward.

15

The step 1 of the reaction C can be carried out under the similar condition to that of reaction A.

The step 2 of the reaction C can be, for example, a hydrolysis reaction, decarboxylation, reducing reaction, amide synthesis, etc. The conditions of the step 2 can be the same as that usually employed by a skilled person in the art.

5


The amino group at position 2 of the pyridine ring in the compounds (I-a), (I-b) and (I-c) is, if necessary, modified according to conventional method to prepare other groups such as alkylamino, alcanoylamino, and the like.

10

Typical procedures for preparing saturated or unsaturated heteroring compounds that are formed by R⁵ and R⁶ in formula I, together with the carbon atoms in the pyridine ring, are as follows.

15

The starting compound is I-d: wherein X, R¹, R², R³ and R⁴ are the same as defined above.



- 26 -

In the step 1 of reaction D, starting compound of formula I-d in a suitable solvent with suitable organic base can be treated with triphosgene by known method to give a desired compound represented by the formula I-D.

5 In the step 1 of reaction E, starting compound of formula I-d in a suitable solvent can be treated with oxidizing agent such as manganese dioxide, nitric acid and pyridinium chlorochromate (PCC) for preparing a compound represented by the formula I-d'-1.

10 In the step 2 of reaction E, a formula I-d'-1 in a suitable solvent can be treated with diethylmalonate and suitable base to give a desired compound represented by the formula I-E.

In the step 1 of reaction F, starting compound of formula I-d in a suitable solvent can
15 be treated with phosphonic ester reagent such as diphenylphosphoryl azide (DPPA) and suitable base for preparing a compound represented by the formula I-d'-2.

In the step 2 of reaction F, compound I-d'-2 can be treated with hydrogen in the presence of a metal catalyst such as palladium on carbon (Pd/C) in a solvent for
20 preparing a compound represented by the formula I-d'-3.

In the step 3 of reaction F, compound I-d'-3 in a suitable solvent can be treated with 1,1'-carbonyldiimidazole (CDI) to give a desired compound formula I-F-1.

25 In the step 4 of reaction F, compound I-d'-3 can be treated with sulfamide and suitable base to give a desired compound represented by the formula I-F-2.

The suitable solvents for the individual steps in the reactions D to F are not limited, but can be selected from the group consisting of ethers, such as dioxane, diethylether,
30 tetrahydrofuran (THF), glycol dimethyl ether, or alcohols such as, propanol, butanol, isopropanol, ethanol diisopropyl ether or esters, such as ethyl acetate, butyl acetate 1,

or aromatic hydrocarbons such as benzene, toluene, xylene, hexane or nitriles such as acetonitrile or amides such as dimethylformamide (DMF), dimethylacetamide or sulfoxides such as dimethyl sulfoxide or halogenated hydrocarbons such as dichloromethane, trichloromethane and others. Having described some examples of
5 suitable solvents, the present examples are illustrative and not restrictive. The suitable solvents for the individual steps can be selected by the person skilled in the art.

The suitable inorganic or organic bases for the individual steps in the reactions D to
10 F are not limited, but can be selected from the group comprising for instance, such as alkaline earth metal or alkali metal hydroxides, alkoxides, acetates, carbonates or bicarbonates, such as, sodium hydroxide, potassium hydroxide or ammonium hydroxide, sodium methoxide, sodium ethoxide, or potassium tert-butoxide, sodium acetate, potassium acetate, calcium acetate or ammonium acetate, sodium carbonate,
15 potassium carbonate or ammonium carbonate, sodium bicarbonate or potassium bicarbonate and also tertiary amines, such as trimethylamine, triethylamine, tributylamine, ethyl-diisopropylamine, N,N-dimethylaniline, N,N-dimethyl-benzylamine, pyridine, picoline, N-methylpiperidine, N-methylmorpholine, N,N-dimethylamino-pyridine, diazabicyclooctane (DABCO), diazabicyclononene (DBN) or diazabicyclo-
20 undecene (DBU). Having described some examples of suitable inorganic and organic bases, the present examples are illustrative and not restrictive. The suitable bases for the individual steps can be selected by the person skilled in the art.

The reaction temperature is optionally set depending on the compounds to be reacted.
25 The reaction temperature is usually about 0°C to 150°C. The reaction is conducted for, usually, 30 minutes to 48 hrs. and preferably 1 to 24 hrs.

When the compound shown by the formula (I) or a salt thereof has geometrical isomers and/or conformational isomers, each of their separated isomer and mixtures
30 are also included in the scope of the present invention.

When the compound shown by the formula (I) or a salt thereof has an asymmetric carbon(s) in the structure, their optically active compounds and racemic mixtures are also included in the scope of the present invention.

- 5 Typical salts of the compound shown by the formula (I) include salts prepared by the reaction of the compound of the present invention with a mineral or organic acid, or an organic or inorganic base. Such salts are known as acid addition and base addition salts, respectively.
- 10 Acids to form acid addition salts include inorganic acids such as, without limitation, sulfuric acid, phosphoric acid, hydrochloric acid, hydrobromic acid, hydroiodic acid and the like, and organic acids, such as, without limitation, p-toluenesulfonic acid, methanesulfonic acid, oxalic acid, p-bromophenylsulfonic acid, carbonic acid, succinic acid, citric acid, benzoic acid, acetic acid, and the like.
- 15 Base addition salts include those derived from inorganic bases, such as, without limitation, ammonium hydroxide, alkaline metal hydroxide, alkaline earth metal hydroxides, carbonates, bicarbonates, and the like, and organic bases, such as, without limitation, ethanolamine, triethylamine, tri(hydroxymethyl)aminomethane,
- 20 and the like. Examples of inorganic bases include, sodium hydroxide, potassium hydroxide, potassium carbonate, sodium carbonate, sodium bicarbonate, potassium bicarbonate, calcium hydroxide, calcium carbonate, and the like.
- Examples of such salts are sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate,
- 25 monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, acetate, propionate, decanoate, caprylate, acrylate, formate, isobutyrate, caproate, heptanoate, propiolate, oxalate, malonate, succinate, suberate, sevacate, fumarate, maleate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methoxybenzoate, phthalate, sulfonate, xylenesulfonate,
- 30 phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, γ -hydroxybutyrate, glycollate, tartarate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate,

naphthalene-2-sulfonate, mandelate, and the like salts of the compound of formula (I).

5 The preferred acid addition salts are those formed with mineral acids, such as, without limitation, hydrochloric acid, and hydrobromic acid, and those formed with organic acids, such as without limitation, maleic acid and methanesulfonic acid. The potassium and sodium salt forms are particularly preferred base addition salts.

10 The compound of the present invention may be administered in oral forms, such as, without limitation normal and enteric coated tablets, capsules, pills, powders, granules, elixirs, tinctures, solution, suspensions, syrups, solid or liquid aerosols and emulsions. They may also be administered in parenteral forms, such as, without limitation, intravenous, intraperitoneal, subcutaneous, intramuscular, and the like forms, well-known to an ordinary skilled person in the pharmaceutical arts.

15 The compounds of the present invention can be administered in intranasal form via topical use of suitable intranasal vehicles, or from transdermal routes, using transdermal delivery systems well-known to an ordinary skilled person in the art.

20 The dosage regimen with the use of the compounds of the present invention is selected by one of ordinary skill in the arts, in view of a variety of factors, including, without limitation, age, weight, sex, and medical condition of the recipient, the severity of the condition to be treated, the route of administration, the level of metabolic and excretory function of the recipient, the dosage form employed, the
25 particular compound and salt thereof employed.

The compounds of the present invention are preferably formulated prior to administration together with one or more pharmaceutically acceptable excipients. Excipients are inert substances such as, without limitation carriers, diluents, flavoring
30 agents, sweeteners, lubricants, solubilizers, suspending agents, binders, tablet disintegrating agents and encapsulating material.

Another embodiment of the present invention is a pharmaceutical formulation comprising the compound of the invention and one or more pharmaceutically acceptable excipients that are compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. Pharmaceutical formulations of the present invention are prepared by combining a therapeutically effective amount of the compound of the invention together with one or more pharmaceutically acceptable excipients therefor. In making the compositions of the present invention, the active ingredient may be mixed with a diluent, or enclosed within a carrier, which may be in the form of a capsule, sachet, paper, or other container. The carrier may serve as a diluent, which may be solid, semi-solid, or liquid material which acts as a vehicle, or can be in the form of tablets, pills, powders, lozenges, elixirs, suspensions, emulsions, solutions, syrups, aerosols, ointments, containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.

For oral administration, the active ingredient may be combined with non-toxic, pharmaceutically acceptable carriers, such as, without limitation, lactose, starch, sucrose, glucose, sodium carbonate, mannitol, sorbitol, calcium carbonate, calcium phosphate, calcium sulfate, methyl cellulose, and the like; together with, optionally, disintegrating agents, such as, without limitation, maize, starch, methyl cellulose, agar bentonite, xanthan gum, alginic acid, and the like; and optionally, binding agents, for example, without limitation, gelatin, acacia, natural sugars, beta-lactose, corn sweeteners, natural and synthetic gums, tragacanth, sodium alginate, carboxy-methyl cellulose, polyethylene glycol, waxes, and the like; and, optionally, lubricants, for example, without limitation, magnesium stearate, sodium stearate, stearic acid, sodium oleate, sodium benzoate, sodium acetate, sodium chloride, talc, and the like.

In powder forms, the carrier may be a finely divided solid which is in admixture with the finely divided active ingredient. The active ingredient may be mixed with a carrier having binding properties in suitable proportions and compacted in the shape and size desired to produce tablets. The powders and tablets preferably contain from
5 about 1 to about 99 weight percent of the active ingredient which is the novel composition of the present invention. Suitable solid carriers are magnesium carboxymethyl cellulose, low melting waxes, and cocoa butter.

10 Sterile liquid formulations include suspensions, emulsions, syrups and elixirs. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable carrier, such as sterile water, sterile organic solvent, or a mixture of both sterile water and a sterile organic solvent.

15 The active ingredient can also be dissolved in a suitable organic solvent, for example, aqueous propylene glycol. Other compositions can be made by dispersing the finely divided active ingredient in aqueous starch or sodium carboxymethyl cellulose solution or in a suitable oil.

20 The formulation may be in unit dosage form, which is a physically discrete unit containing a unit dose, suitable for administration in human or other mammals. A unit dosage form can be a capsule or tablets, or a number of capsules or tablets. A "unit dose" is a predetermined quantity of the active compound of the present invention, calculated to produce the desired therapeutic effect, in association with one or more excipients. The quantity of active ingredient in a unit dose may be
25 varied or adjusted from about 0.1 to about 1000 milligrams or more according to the particular treatment involved.

30 Typical oral dosages of the present invention, when used for the indicated effects, will range from about 0.01mg/kg/day to about 100mg/kg/day, preferably from 0.1 mg/kg/day to 30 mg/kg/day, and most preferably from about 0.5 mg/kg/day to about 10 mg/kg/day. In case of parenteral administration, it has generally proven

advantageous to administer quantities of about 0.001 to 100 mg/kg/day, preferably from 0.01 mg/kg/day to 1mg/kg/day. The compounds of the present invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses, two, three, or more times per day. Where delivery is via transdermal forms, of course, administration is continuous.

The effects of the compounds of the present invention were examined by the following assays and pharmacological tests.

IKK- β kinase inhibitory assay.

(1) Preparation of IKK- β kinase protein.

A cDNA fragment encoding human IKK- β open reading frame was generated by PCR with the use of a pair of primers designed from the published sequence (Woronicz JD et al. (1997) Science 278,866-869). A template was obtained from Quickclone cDNA (Clontech) using ElongaseTM Amplification kit (Life Technologies). The DNA fragments generated by PCR were gel-purified and subcloned into pBluescript. The cDNA fragment cloned in pBluescript was inserted into pcDNA3.1/His C KpnI/NotI, and transferred into pVL1393 SmaI/XbaI (Pharming) to construct a baculovirus transfer vector. Then the vector, together with the linearized baculovirus (BaculoGoldTM, Pharmingen) was used to transfect Sf21 cells (Invitrogen, San Diego, CA). Generated recombinant baculovirus was cloned and amplified in Sf21 cells, grown in TNM-FH insect cell medium (Life Technologies, Inc.) supplemented with 10% FCS, 50 g/ml Gentamycin, 0.1% Pluronic F-68 (Life Technologies, Inc.) as suspension culture (200 ml in 1 L Erlenmeyer flask; 27°C; 130 rpm). Sf21 cells were infected with this amplified virus with a multiplicity of infection of 5 following standard protocols (Crossen R, Gruenwald S (1997) Baculovirus Expression Vector System Instruction Manual, Pharmingen Corporation) and harvested 48 hrs.

later. The cells were lysed to obtain the produced chimeric protein of IKK- β kinase fused by histidine (His-tagged IKK- β).

(2) The preparation of purified GST-I κ B α fusion proteins

5

An expression vector containing the nucleotide sequence encoding fusion protein of GST with amino acid residues 1 to 54 of I κ B α under the control of an IPTG-inducible promoter was constructed. The expression vector was introduced in *E. coli* and the transformant was cultured and lysed to obtain a GST-I κ B α fusion protein. Then the resulting GST-I κ B α fusion protein was purified and biotinized for kinase assay.

10

(3) The measurement of IKK- β kinase activity

15

The 96-well format kinase assay of IKK- β was performed to test the inhibitory activity of the compounds of the present invention. First, 5 μ l of a test compound was put in the presence of 2.5% dimethyl sulfoxide (DMSO) in each well in a U-bottomed 96-well plate (Falcon). For control wells of background (BG) and total phosphorylation (TP), 5 μ l of 2.5% DMSO was put. Recombinant IKK- β (final 0.6 μ g/ml) and bio-GST-I κ B α (1-54) (final 0.2 μ M) were diluted in 25 μ l of 2 x kinase buffer β (40mM Tris-HCl, pH 7.6, 40 mM MgCl₂, 40mM β -glycerophosphate, 40mM p-nitrophenyl-phosphate, 2mM EDTA, 40mM creatine phosphate, 2mM DTT, 2 mM Na₃VO₄, 0.2 mg/ml BSA and 0.8mM phenylmethylsulfonyl fluoride) and transferred to the 96-well plate. Bio-GST-I κ B α (1-54) in 25 μ l of 2 x kinase buffer β without IKK- β was transferred to BG wells. Then 20 μ l of 12.5 μ M ATP, 62.5 μ Ci/ml [γ -³³P] ATP (Amersham Pharmacia Biotech) was added and the resulting mixture was incubated for 2 hrs. at room temperature. The kinase reactions were terminated by the addition of 150 μ l of termination buffer (100 mM EDTA, 1 mg/ml BSA, 0.2mg NaN₃). One hundred and fifty μ l of the sample was transferred to a streptavidin-coated, white MTP (Steffens Biotechnische Analysen GmbH #08114E14.FWD) to capture the biotinylated

20

25

30

- 34 -

substrates. After 1 hr. of incubation, non-bound radioactivity was eliminated by washing the wells five times with 300 μ l of washing buffer including 0.9% NaCl and 0.1% (w/v) Tween-20 with the use of a MW-96 plate washer (BioTec). The bound radioactivity was determined after the addition of 170 μ l MicroScint-PS scintillation cocktail (Packard) using a TopCount scintillation counter.

Syk tyrosine kinase inhibitory assay for selectivity.

10 (1) Preparation of Syk protein

A cDNA fragment encoding human Syk openreading frame was cloned from total RNA of human Burkitt's lymphoma B cell lines, Raji (American Type Culture Collection), with the use of RT-PCR method. The cDNA fragment was inserted into pAcG2T (Pharmingen, San Diego, CA) to construct a baculovirus transfer vector. Then the vector, together with the linearized baculovirus (BaculoGoldTM, Pharmingen), was used to transfect Sf21 cells (Invitrogen, San Diego, CA).

Generated recombinant baculovirus was cloned and amplified in Sf21 cells. Sf21 cells were infected with this amplified high titer virus to produce a chimeric protein of Syk kinase fused by glutathione-S-transferase (GST).

The resulting GST-Syk was purified with the use of glutathione column (Amersham Pharmacia Biotech AB, Uppsala, Sweden) according to the manufacturer's instruction. The purity of the protein was confirmed to be more than 90% by SDS-PAGE.

(2) Synthesize of a peptide

5 Next, a peptide fragment of 30 residues including two tyrosine residues, KISDFGLSKALRADENYYKAQTHGKWPVKW, was synthesized by a peptide synthesizer. The N-terminus of the fragment was then biotinylated to obtain biotinylated activation loop peptide (AL).

(3) The measurement of Syk tyrosine kinase activity

10 All reagents were diluted with the Syk kinase assay buffer (50mM Tris-HCl (pH 8.0), 10mM MgCl₂, 0.1mM Na₃VO₄, 0.1% BSA, 1 mM DTT). First, a mixture (35 µl) including 3.2µg of GST-Syk and 0.5µg of AL was put in each well in 96-well plates. Then 5µl of a test compound in the presence of 2.5% dimethyl sulfoxide (DMSO) was added to each well. To this mixture was
15 added 300µM ATP (10 µl) to initiate the kinase reaction. The final reaction mixture (50 µl) consists of 0.65 nM GST-Syk, 3µM AL, 30µM ATP, a test compound, 0.25% DMSO, and a Syk kinase assay buffer.

20 The mixture was incubated for 1 hr. at room temperature, and the reaction was terminated by the addition of 120µl of termination buffer (50 mM Tris-HCl (pH 8.0), 10mM EDTA, 500mM NaCl, 0.1% BSA). The mixture was transferred to streptavidin-coated plates and incubated for 30 minutes. at room temperature to combine biotin-AL to the plates. After washing the plates with Tris-buffered saline (TBS) (50mM Tris-HCl (pH 8.0), 138mM NaCl, 2.7mM KCl) containing 0.05% Tween-20 for 3 times, 100µl of antibody
25 solution consisting of 50 mM Tris-HCl (pH 8.0), 138mM NaCl, 2.7mM KCl, 1% BSA, 60ng/ml anti-phosphotyrosine monoclonal antibody, 4G10 (Upstate Biotechnology), which was labeled with europium by Amersham Pharmacia's kit in advance, was added and incubated at room temperature for 60 minutes.
30 After washing, 100µl of enhancement solution (Amersham Pharmacia Biotech) was added and then time-resolved fluorescence was measured by

multi-label counter ARVO (Wallac Oy, Finland) at 340nm for excitation and 615nm for emission with 400 msec of delay and 400 msec of window.

The measurement of RANTES production in response to TNF- α from A549 cells.

5

(1) Preparation of A549 cells

The A549 human lung epithelium cell line (ATCC #CCL-885) was maintained in Dulbecco's modified Eagle's medium (D-MEM, Nikken Biomedical Institute) supplemented with 10% FCS (Gibco), 100U/ml penicillin, 100 μ g/ml streptomycin, and 2mM glutamine (culture medium). Forty thousand (4×10^4) cells (80 μ l/well) were seeded in each well of 96 well flat-bottom tissue culture plate (Falcon #3072). The plate was allowed to stand for 2 hrs., thus the cells were adhered to the bottom of each well. To the each well was added 10 μ l vehicle (1% DMSO), serial dilutions of test compounds in 1% DMSO, or 5nM Dexamethasone in 1% DMSO as a reference. The mixture (90 μ l/well) was incubated for 1 hr. at 37°C. After 1 hr., 1 μ g/ml TNF- α (10 μ l) in culture medium was added to the mixture to obtain 100 μ l of reaction mixture. The reaction mixture was cultured for 24 hrs. to stimulate the cells with 100ng/ml TNF- α . Cells with vehicle without TNF- α stimulation were also prepared.

(2) Enzyme immunoassay

Then the concentration of RANTES released from the cells in the supernatants of each well was determined using a quantitative sandwich enzyme immunoassay technique. First, 2 μ g/ml mouse anti-huRANTES mAb (R&D Systems, #mAb678) in PBS buffer (pH 7.4, 100 μ l) was put in each well of 96-well NUNC fluoro plate (Nalge Nunc, New York USA) (Final 200ng/well) and the plate was allowed to stand for overnight at 4°C to be coated by the antibody. Each well of the plate was then washed with 350 μ l wash buffer (0.05% Tween-20, 0.85% NaCl, and 25mM Tris/HCl pH7.4) for three times. Blocking buffer containing 1% BSA (Sigma 99% pure, 100g),

5% sucrose (Nacalai tesque, 99% pure, 500 g), and 0.02% azide (Nacalai tesque, 100%, 500 g) were added (200 μ l) to each well and then the plate was allowed to stand for 4 hrs. to stabilize the coated antibody.

5 Next, 50 μ l supernatants of cell culture prepared in (1) above were put in each well of the 96-well NUNC fluoro plate with coated antibody. Recombinant Human RANTES (Pepro Tech, Inc. #300-06) was used as the standard for the determination of RANTES production (linear range between 1 and 10 ng/ml). Eu-labelled mouse anti-huRANES mAb (60ng/ml: R&D Systems, #mAb278)
10 in PBS supplemented by 1% BSA and 0.05% Tween 20 was added (50 μ l) to each well. The reaction mixtures were incubated at room temperature for 4 hrs. After washing with wash buffer (0.05% Tween-20, 0.85% NaCl, and 25mM Tris/HCl pH7.4, 350 μ l/well) for 5 times with the use of a Sera Washer (Bio-Tech, #MW-96R), the enhancement solution (DELFLIA, #1244-405,
15 100 μ l/well) was added to each well. The plate was incubated for 10 minutes at room temperature with moderate shaking. Fluorescent intensity was measured using a DELFLIA fluorimeter (Wallac). Excitation was performed at 340nm and emission was measured at 615nm.

20 The measurement of IL-2 production in Jurkat T cells in response to antibody stimulation.

IL-2 production was measured in Jurkat T cells (E6-1 clone; ATCC # TIB-152) in response to stimulation with anti-CD3/anti-CD28 antibodies.

25

(1) Preparation of immobilized antibodies

First, anti-CD3 antibodies (400 ng/well Nichirei, NU-T3 4 μ g/ml in 100 μ l Dulbecco's PBS) were put in each well of 96-well plate (Falcon #3072) and the plate was allowed to stand for 2 hrs. at room temperature to be coated
30 with the antibody. Each well of the plate was then washed with 250 μ l PBS 3 times.

(2) Preparation of Jurkat cell culture

Jurkat T cells were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 U/ml penicillin G, and 100 µg/ml streptomycin (culture medium). Two hundred thousand (2×10^5) cells (190 µl/well) were seeded in each well of 96-well U-bottom tissue culture plates (Falcon #3077). To each well was added 10 µl vehicle (0.2% DMSO), serial dilution of compounds in 0.2% DMSO, or 25 nM cyclosporin A as a reference in 0.2% DMSO. The mixture (200 µl) was incubated for 1 hr. at 37°C in a humidified 5% CO₂ environment.

(3) Stimulation of the cell

The reaction mixture obtained in (2) (100 µl) was put in the each well of the antibody-immobilized plate prepared in (1). To this well was added anti-CD28 antibodies (Nichirei, KOLT-2, 6 µg/ml in cell culture medium, 50 µl/well) and 2.5 µg/ml goat anti-mouse kappa chain antibodies (Bethyl Laboratories, (Cat#A90-119A) 10 µg/ml in culture medium, 50 µl/well). The reaction mixture in each well was incubated for 24 hrs. at 37°C to stimulate cells with immobilized anti-CD3 antibodies (400 ng/well) and anti-CD28 antibodies (1.5 µg/ml), and then to cross-link receptors on the cells with anti-mouse kappa chain antibodies (2.5 µg/ml).

(4) Measurement of IL-2 production

The supernatants of the reaction mixture were then collected. The IL-2 concentration in the supernatants was determined using a DuoSet™ ELISA Development Kit (GenzymeTechno, Minneapolis, USA) following the manufacturer's recommendations. First, 2 µg/ml of mouse anti-huIL-2 Ab in PBS buffer (100 µl) was put in each well of 96-well plate (NUNC, Maxisorp™) and the plate was allowed to stand for overnight at 4°C to be coated with the antibody. Each well of the plate was then washed 5 times with 350 µl of wash buffer containing PBS, 0.05% Tween 20 (Nakalai tesque) using Sera

Washer (Bio-Tech, #MW-96R). To each well was added 250µl of 1% BSA (Sigma) in PBS, 0.05% Tween 20 (dilution buffer). After 2 hrs. incubation at room temperature, the buffer was discarded, and 50µl of culture medium was added. Next, 50µl supernatant of stimulated cell culture prepared (3) above was put in each well of the 96-well plate with coated mouse anti-huIL-2 antibody. Recombinant Human IL-2 (Genzyme Techne) was used as the standard for the determination of IL-2 production (linear range between 200 and 5,400pg/ml). The reaction mixtures were incubated for 1 hr. at room temperature. After 5 times washing, 100µl biotinylated rabbit anti-huIL-2 antibody (Genzyme Techne, 1.25µg/ml) in dilution buffer was added to each well, and incubated at room temperature for 1 hr. After 5 times washing, 100µl of Streptavidin-conjugated horseradishperoxidase (Genzyme Techne, 1/1000 in dilution buffer) was added to each well. After 20 minutes, each well of the plate was washed 5 times with wash buffer (350 µl/well). Substrate and H₂O₂ (TMBZ peroxidase detection kit, SUMILON #ML-1120T) were added to the mixture and the mixture was allowed to stand at room temperature. The reaction was terminated after 10 minutes by adding 2N H₂SO₄. Optical density at 450nm was measured with the use of a microplate reader (Labosystems, Multiscan Multisof). Quantification of IL-2 production in each sample was performed by comparison of optical densities between each sample and the standard curve.

Mouse LPS-induced TNF-α production

Eight weeks old BALB/c female mice were placed into two groups, a control group and a treated group. A solution containing 200µg/mouse of LPS in 0.9% physiological salt was administered by intraperitoneal (i.p.) injection into the control mice. Mice in the treated group were first injected i.p. with compounds of the present invention 30 minutes prior to the LPS injection. Under anesthesia with pentobarbital (80mg/kg, i.p.), blood was collected from the posterior venous cavity of the treated and control mice at 90 min post-LPS injection into 96-well plate

containing 2% EDTA solution. The plasma was separated by centrifugation at 1800 rpm for 10 minutes at 4°C and then diluted with four times volumes of phosphate buffer saline (pH 7.4) containing 1% bovine serum albumin. TNF- α concentration in the sample was determined using an ELISA kit (Pharmingen, San Diego, CA.)

The mean TNF- α level in 5 mice from each group was determined and the percent reduction in TNF- α levels was calculated. The treated mice showed significant decrease in the level of TNF- α as compared to the control mice. The result indicates that the compounds of the present invention can restrain LPS-induced cytokine activity.

The results of a in vitro test and cellular assay tests (A549 and Jurkat) are shown in the tables in the Examples below. The data corresponds to the compounds as yielded by solid phase synthesis and thus to levels of purity of about 40 to 90%. For practical reasons, the compounds are grouped in four classes of activity as follows:

In vitro IC_{50} = A 0.5 μ M < B 2 μ M < C 10 μ M < D

Cellular IC_{50} = A 1 μ M < B 10 μ M < C

The compounds of the present invention also show excellent selectivity, and strong activity in vivo assays.


EXAMPLES

The present invention will be described in detail below in the form of examples, but they should by no means be construed as defining the metes and bounds of the present invention.

In the examples below, all quantitative data, if not stated otherwise, relate to percentages by weight. ^1H NMR spectra were recorded using either Bruker DRX-300 (300MHz for ^1H) spectrometer in CDCl_3 . Chemical shifts are reported in parts per million (ppm) with tetramethylsilane (TMS) as an internal standard at zero ppm. Coupling constant (J) are given in hertz and the abbreviations s, d, t, q, m, and br refer to singlet, doublet, triplet, quartet, multiplet, and broad, respectively. The mass determinations were carried out by MAT95 (Finnigan MAT).

Preparing method of starting compounds:


Starting compound 1A :2-Benzyloxyacetophenone



A mixture of 2'-hydroxyacetophenone (68.1g, 0.500mol), benzylbromide (65.4ml, 94.1g, 0.550mol) and K_2CO_3 (103g, 0.750mol) in acetone (1.00L) was stirred and heated to reflux overnight. The resulting mixture was concentrated under reduced pressure to obtain a residue. The obtained residue was dissolved in the mixture of AcOEt and water and then extracted with AcOEt. The extract was washed with brine, dried over magnesium sulfate, filtered, and concentrated under reduced pressure to give a crude material. The crude material was purified by distillation

under reduced pressure to give starting compound 1A as a colorless oil (100g, yield 88%).

Starting compound 1A': 1-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy] phenyl}ethanone




To a stirred solution of 1-(2,6-dihydroxyphenyl)ethanone (50.0 g, 328 mmol) in acetone (1000 mL) was added potassium carbonate (227 g, 1643 mmol) and (bromomethyl)cyclopropane (35.1 mL, 361 mmol). The mixture was stirred at 50°C for 2 days. The reaction mixture was filtrated on celite, and then the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate. The separated organic phase was washed with water and brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The residue was suspended in hexane. Then the suspension was stirred at 80°C for 30 minuets. The solution was filtered and the filtrate was allowed to cool to room temperature. The resulting white solid was collected by filtration, washed with hexane, and dried under reduced pressure to give 1-{2-[(cyclopropylmethyl)oxy]-6-hydroxyphenyl}ethanone as a pale yellow solid (56.3 g, yield; 83%).

To a stirred solution of 1-{2-[(cyclopropylmethyl)oxy]-6-hydroxyphenyl} ethanone (56.3 g, 272 mmol) in acetone (1000 mL) was added potassium carbonate (188 g, 1364 mmol), 4-methoxybenzyl chloride (40.9 mL, 300 mmol) and tetrabutyl-ammonium iodide (20.2 g, 54.6 mmol). The mixture was stirred at reflux overnight.


The reaction mixture was allowed to cool to room temperature, filtered on Celite, and then the filtrate was concentrated under reduced pressure. The residue was diluted with water and extracted with ethyl acetate. The separated organic phase was washed with brine, dried over MgSO_4 , filtered and concentrated under reduced pressure. Then the resulting white solid was recrystallized from ethanol, collected by filtration, washed with ethanol, and dried under reduced pressure to give starting compound 1A' as a white solid (79.2 g, yield; 89%).

Starting compound 1B :2'-[tert-butyl(dimethyl)silyl]oxyacetophenone



To a stirred solution of 2'-hydroxyacetophenone (10.00 g, 73.45 mmol) in DMF (150 mL) were added imidazole (6.00 g, 88.14 mmol) and tert-butyl dimethylchlorosilane (12.18 g, 80.79 mmol). The mixture was stirred at room temperature for 60 hrs., and then diluted with diethyl ether. The resulting organic phase was washed with water, aqueous potassium hydrogen sulfate solution, and brine, successively. Then the washed organic phase was dried over magnesium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica-gel (hexane: ethyl acetate, 9:1 - 4:1) to give starting compound 1B as a colorless oil (19.83 g, yield 92%).


Starting compound 1C :3-Benzyloxypicolinonitrile



- 44 -


A suspension of 3-hydroxypicolinonitrile (3.00 g, 25.0 mmol), which was prepared according to Synthesis 316 (1983) and J. Org. Chem. 48,1375(1983), potassium carbonate (5.40 g, 39.1 mmol) and benzyl bromide (5.10 g, 29.8 mmol) in acetone (150 mL) was stirred at room temperature for 20 hrs. The reaction mixture was
5 filtrated and the filtrate was evaporated. The residue was purified by column chromatography on silica gel (ethyl acetate : n-hexane = 1:3 to 1:2) and recrystallization from ethyl acetate : n-hexane = 1:4 to give starting compound 1C as a colorless powder (4.354g, yield 83%).

10 **Starting compound 1D :2-Acetyl-3-benzyloxy pyridine**



To a cold solution (0°C) of 3-benzyloxy-picolinonitrile (2.50 g, 11.9 mmol) in tetrahydrofuran (100 mL) was added 0.92M methylmagnesium bromide in tetrahydrofuran (150 mL, 138 mmol) and stirred at 0°C for 30 minutes then at room
15 temperature for 4 hrs. The reaction mixture was poured into water (2 L) and acidified by 10% sulfuric acid (500 mL). After stirring for 30 minutes, the reaction mixture was added to sodium bicarbonate (100 g) slowly and extracted into ethyl acetate. The resulting organic phase was washed with saturated sodium chloride, dried anhydrous Na₂SO₄, filtrated, and evaporated. The residue was purified by column chromatography on silica gel(ethyl acetate:n-hexane, 1:3) to give starting compound 1D as a
20 colorless oil (2.49 g, yield 92%).


Starting compound 2 : 2-amino-4-(3-aminophenyl)-6-(2-{{tert-butyl(dimethyl)-silyl}oxy}phenyl)nicotinonitrile



A mixture of 2'-[tert-butyl(dimethyl)silyl]-oxyacetophenone (starting compound 1B, 20.0 g, 79.9 mmol), 3-nitrobenzaldehyde (12.1 g, 79.9 mmol), malononitrile (5.3 g, 79.9 mmol), ammonium acetate (9.2 g, 119.8 mmol) and toluene (25 mL) was stirred under reflux for 3 hrs. The reaction mixture was extracted with ethyl acetate and water. The separated organic phase was dried over Na₂SO₄, filtrated, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica gel (hexane/ ethyl acetate, 9:1 – 4:1) to give 2-amino-6-(2-{{tert-butyl(dimethyl)silyl}-oxy}phenyl)-4-(3-nitrophenyl)nicotinonitrile as a white solid (6.5 g, 18%).

A mixture of 2-amino-6-(2-{{tert-butyl(dimethyl)-silyl}oxy}phenyl)-4-(3-nitrophenyl)nicotinonitrile (3.2 g, 7.2 mmol), 10% Pd-C (0.25 g) and ethyl acetate (1 L) was stirred at room temperature for 12 hrs. under a hydrogen atmosphere (2.5 atm). The reaction mixture was filtered on Celite Pad and the filtration was concentrated under reduced pressure to give starting compound 2, which was used for the next step without further purification (2.6 g, yield 87%).

Starting compound 3 : 2-amino-4-[3-amino-4-(1-pyrrolidinyl)phenyl]-6-(2-benzyloxyphenyl)nicotinonitrile




A mixture of 2-benzyloxyacetophenone (5.00 g, 22.10 mmol), 4'-chloro-3'-nitro-
5 benzaldehyde (8.20 g, 44.19 mmol), malononitrile (2.92 g, 44.19 mmol), and
ammonium acetate (8.52 g, 110.48 mmol) in toluene (15 mL) was stirred at 130°C
for 3 hrs. After cooled to room temperature, the mixture was diluted with ethyl
acetate and THF. The organic phase was washed twice with water, dried over
Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was
10 suspended in ethanol. The precipitate was collected by filtration, washed with ethyl
acetate, and dried under reduced pressure to give 2-amino-6-(2-benzyloxyphenyl)-4-
(4-chloro-3-nitrophenyl)nicotinonitrile as a white solid (6.40 g, yield 63%).

To a cold (0°C) solution of 2-amino-6-(2-benzyloxyphenyl)-4-(4-chloro-3-nitro-
15 phenyl)nicotinonitrile (1.000 g, 2.189 mmol) in DMF (10 mL) was added pyrrolidine
(0.778 g, 10.943 mmol). The mixture was stirred at room temperature for 2hrs. and
then at 60°C for 2 hrs. The reaction mixture was partitioned between ethyl acetate
and water. The separated organic phase was washed with brine, dried over Na₂SO₄,
filtered, and concentrated under reduced pressure. The residue was suspended in
20 ethanol, and the precipitate was collected by filtration, washed with ethyl acetate and
dried under reduced pressure to give 2-amino-6-(2-benzyloxyphenyl)-4-[3-nitro-4-(1-
pyrrolidinyl)phenyl] nicotinonitrile as a yellow solid (0.990 g, yield 92%).

To a suspension of 2-amino-6-(2-(benzyloxy)phenyl)-4-[3-nitro-4-(1-pyrrolidinyl)-phenyl]nicotinonitrile (1.000 g, 2.034 mmol) and Fe powder (3.000 g) in ethanol (180 mL) were added water (10 mL) and then ammonium chloride (1.000 g). The mixture was stirred under reflux for 3 hrs. The mixture was filtered on Celite Pad and the filtrate was concentrated under reduced pressure. The residue was suspended in ethanol, and the precipitate was collected by filtration, washed with ethyl acetate, and dried under reduced pressure to give starting compound 3 as a white solid (0.700 g, yield 75%).

Starting compound 4 :2-amino-4-[3-amino-4-(dimethylamino)phenyl]-6-{2-[(4-methoxybenzyl)oxy]phenyl}nicotinonitrile




A mixture of 2-(4-methoxybenzyloxy)acetophenone (5.663 g, 22.097mmol), 4'-chloro-3'-nitrobenzaldehyde (8.201 g, 44.193 mmol), malononitrile (2.920 g, 44.193 mmol), and ammonium acetate (8.516 g, 110.486 mmol) in toluene (15 mL) was stirred at 130°C for 4 hrs. The reaction mixture was partitioned between ethyl acetate and water. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was suspended with ethanol. The resulting solid was collected by filtration, washed with ethanol, ethyl acetate and diethyl ether, and dried under reduced pressure to give 2-amino-4-(4-chloro-3-nitrophenyl)-6-{2-[(4-methoxybenzyl)oxy]phenyl}-nicotinonitrile as a white solid (5.560 g, yield 52%).

To a stirred solution of 2-amino-4-(4-chloro-3-nitrophenyl)-6-{2-[(4-methoxybenzyl)oxy]phenyl}-nicotinonitrile (0.850 g, 1.746 mmol) in DMF (5 mL) including triethylamine (1.2 mL) was added dimethylamine hydrochloride (0.996 g, 12.220 mmol), and the mixture was stirred at 70°C for 3 hrs. The reaction mixture was quenched with water and extracted with ethyl acetate. The organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was suspended in ethanol. The resulting solid was collected by filtration, washed with ethanol, and dried under reduced pressure to give 2-amino-4-[4-(dimethylamino)-3-nitrophenyl]-6-{2-[(4-methoxybenzyl)-oxy]phenyl}nicotinonitrile as an orange oil (0.820 g, yield 95%).

To a stirred suspension of 2-amino-4-[4-(dimethylamino)-3-nitrophenyl]-6-{2-[(4-methoxybenzyl)oxy]phenyl}nicotinonitrile (0.815 g, 1.654 mmol) in ethanol (150 mL) were added Fe powder (5.000 g), water (20 mL) and ammonium chloride (1.000 g). The mixture was stirred under reflux for 12 hrs. The reaction mixture was cooled to room temperature, filtered on Celite Pad. The filtrate was concentrated under reduced pressure. The residue was suspended in ethanol. The resulting solid was collected by filtration, washed with ethanol and water, and dried under reduced pressure to give starting compound 4 as an orange solid (0.500 g, yield 65%).

Starting compound 5 :3-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)oxy]phenyl}-4-pyridinyl)benzoic acid




A mixture of 2-[(4-methoxybenzyl)oxy]acetophenone (0.26 g, 1.00 mmol), methyl 3-formbenzoate (0.16 g, 1.00 mmol), malononitrile (0.07 g, 1.00 mmol), and am-

monium acetate (0.23 g, 3.00 mmol) in xylene (10 mL) was heated at 120°C (bath temperature) overnight. The resulting mixture was concentrated under reduced pressure, and the residue was diluted with water and extracted with ethyl acetate. The separated organic phase was washed with brine, dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude material was purified by column chromatography on silica gel (hexane: ethyl acetate, 70:30) to give 2-amino-6-{2-[(4-methoxybenzyl)oxy]phenyl}-4-(3-methoxycarbonylphenyl)-nicotinonitrile (0.200 g, yield 43%).

A mixture of 2-amino-6-{2-[(4-methoxybenzyl)-oxy]phenyl}-4-(3-methoxycarbonylphenyl)-nicotinonitrile (0.20 g, 0.43 mmol), 4N NaOH solution (1.0 mL), and THF (5.0 mL) was stirred at room temperature overnight. The reaction mixture was poured into water and extracted with ethyl ether twice. To the separated aqueous phase was added 1N KHSO₄ solution until the mixture became acidic. The resulting precipitate was collected by filtration and dried under reduced pressure to give the stating compound 5 as a gray powder (0.16 g, yield 81%).

Starting compound 6 :tert-butyl 2-amino-4-(3-aminophenyl)-6-(2-hydroxyphenyl)nicotinate



A mixture of 2'-benzyloxyacetophenone (3.00 g, 13.25 mmol), 3'-nitrobenzaldehyde (2.00 g, 13.25 mmol), tert-butyl cyanoacetate (1.87 g, 13.25 mmol), ammonium acetate (3.07 g, 39.77 mmol) in p-xylene (10 mL) was stirred at 120°C for 2 hrs.


- 50 -

After cooled to room temperature, the reaction mixture was partitioned between ethyl acetate and water. The separated organic phase was washed with brine, dried over Na₂SO₄, filtrated, and concentrated under reduced pressure. The crude product was purified by column chromatography on silica-gel (hexane: ethyl acetate, 5:1 - 2:1) to give tert-butyl 2-amino-6-[2-(benzyloxy)phenyl]-4-(3-nitrophenyl)nicotinate as a yellow oil (2.51 g, yield 38%).

A mixture of tert-butyl 2-amino-6-[2-(benzyloxy)-phenyl]-4-(3-nitrophenyl)-nicotinate (2.50 g, 5.02 mmol) and 10% Pd-C (0.20 g) in ethyl acetate (20 mL) was stirred at 2 atm under a hydrogen atmosphere for 5 hrs. The mixture was filtered on Celite Pad to remove Pd-C and washed with ethyl acetate. The filtrate was concentrated under reduced pressure, and the residue was purified by column chromatography on silica-gel (hexane: ethyl acetate, 4:1 - 3:2) to give starting compound 6 as a pale yellow oil (1.05 g, yield 56%).

Example 1-1

N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-5-oxotetrahydro-2-furancarboxamide



To a cold (0°C) mixture of pyridine (0.20 mL, 2.424 mmol), 2-amino-4-(3-aminophenyl)-6-(2-[[tert-butyl(dimethyl)silyl]oxy]phenyl)nicotinonitrile (starting compound 2, 1.010 g, 2.424 mmol), acetonitrile (10 mL) and THF (2 mL) was added

dropwise a solution of 5-oxotetrahydro-2-furancarbonyl chloride (0.360 g, 2.424 mmol) in acetonitrile (4 mL). The mixture was stirred for 2 hrs., allowed to warm to room temperature, stirred for 1 hr., and extracted with ethyl acetate and water. The separated organic phase was washed with brine, dried over Na₂SO₄,
5 filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica-gel (hexane: Ethyl acetate, 7:3 - 5:5) to give N-{3-[2-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-3-cyano-4-pyridinyl]phenyl}-5-oxotetrahydro-2-furancarboxamide as a white solid (0.982 g, yield 77%).

10 To a cold (0°C) solution of N-{3-[2-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-3-cyano-4-pyridinyl]phenyl}-5-oxotetrahydro-2-furancarboxamide (0.400 g, 0.757 mmol) in THF (5 mL) was added dropwise a solution n-tetrabutylammonium fluoride in THF (1M, 2 mL). After being stirred for 30 minutes, the mixture was quenched with water (5 mL). The resulting precipitate was collected by filtration,
15 washed with water and ethanol, and dried under reduced pressure to give N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-5-oxotetrahydro-2-furancarboxamide as a white solid (0.293 g, yield 93%).

Molecular weight: 414.424


Mass spectrometry: 415

20 Melting point: 155 dec

In vitro activity grade: B

Cellular activity grade: (A954)-B

¹H-NMR(300 MHz, DMSO-d₆): 2.23 - 2.38 (2H, m), 2.55 - 2.59 (2H, m), 5.08 - 5.12 (1H, m), 6.87 - 6.93 (2H, m), 7.32 - 7.47 (4H, m), 7.50 - 7.56 (2H, m), 7.82 (1H, d, J = 8.3 Hz), 7.91 (1H, s), 8.02 (1H, d, J = 8.0 Hz), 10.47 (1H, s).
25

Example 1-2**Sodium 5-({3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-amino)-4-hydroxy-5-oxopentanoate**

5

To a suspension of N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-phenyl}-5-oxotetrahydro-2-furancarboxamide (0.250 g, 0.603 mmol) in methanol (10 mL) was added dropwise 2N NaOH solution (0.3 mL). After the mixture was stirred for 10 minutes, insoluble solid was filtered off. The filtrate was concentrated under reduced pressure and the residue was crystallized from methanol and ethyl ether. The resulting solid was collected by filtration under an argon atmosphere, washed with ethyl ether, and dried under reduced pressure to give Sodium 5-({3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}amino)-4-hydroxy-5-oxopentanoate as a pale yellow solid (0.165 g, yield 60%).

10

15

Molecular weight: 454.421

Mass spectrometry: 433

Melting point: 199 dec

In vitro activity grade: B

Cellular activity grade: (A954)-C

20






¹H-NMR (300 MHz, DMSO-d₆): 1.72 - 1.98 (2H, m), 2.18 - 2.25 (2H, m), 4.01 (1H, dd, J = 3.2, 7.5 Hz), 6.60 - 6.85 (2H, m), 7.09 - 7.30 (3H, m), 7.32 (1H, d, J = 7.9 Hz), 7.46 (1H, t, J = 7.9 Hz), 7.67 (1H, br), 7.93 (1H, d, J = 8.2 Hz), 8.01 - 8.05 (2H, m), 9.91 (1H, s), 10.38 (1H, br s).

Examples 1-03 to 1-23






In the similar manners as described in Example 1-01 and Example 1-02 above, compounds in Examples 1-03 to 1-23 as shown in Table 1 were synthesized.






5


Table 1

EX No	STRUCTURE	mol weight	MS	A549	invitro
1-03	 CH	450,885	415	C	B
1-04		374,403	375	C	B
1-05		413,440	414	C	C
1-06		380,428	381	B	C
1-07	 CH CH	375,260	303	C	C

EX No	STRUCTURE	mol weight	MS	A549	invitro
1-08		302,338	303	C	D
1-09		497,852	418	C	A
1-10		454,421	432	C	A
1-11		428,451	429	C	D
1-12		444,451	445	C	B


EX No	STRUCTURE	mol weight	MS	A549	invitr
1-13		484,448	463	C	B
1-14		344,376	345	C	D
1-15		488,867	467	C	A
1-16		472,412	451	C	B
1-17		488,867	467	C	C

EX No	STRUCTURE	mol weight	MS	A549	invitro
1-18		484,448	463	C	C
1-19		438,422	417	C	B
1-20		415,412	416	C	C
1-21		303,326	304	B	C
1-22		455,409	434	C	B

EX No	STRUCTURE	mol weight	MS	A549	invitro
1-23		417,347	304	B	A

Example 2-1

5 N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-(1-piperidinyl)propanamide hydrochloride



10 To a cold (0°C) solution of 3-(1-piperidinyl)-propanoic acid (0.676 g, 3.601 mmol) in dichloromethane was added oxalyl chloride (0.471 mL, 5.401 mmol) and stirred at room temperature for 12 hrs. The mixture was concentrated under reduced pressure. The residue was added to the solution of 2-amino-4-(3-aminophenyl)-6-(2-[[tert-butyl(dimethyl)silyl]oxy]-phenyl)nicotinonitrile (starting compound 2, 1.500 g, 3.601 mmol) in acetonitrile (3 mL), and the resulting mixture was stirred at 0°C for 15 1 hr. The reaction mixture was extracted with ethyl acetate and water. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. Purification was carried out by silica gel column chromatography (chloroform / methanol =10/1) to give N-{3-[2-amino-6-(2-[[tert-butyl(di-

methoxy)silyl]oxy}phenyl)-3-cyano-4-pyridinyl]phenyl}-3-(1-piperidinyl)propanamide as a white solid (0.860g, yield 45%).

To a stirred solution of N-{3-[2-amino-6-(2-{[tert-butyl(dimethyl)silyl]oxy}phenyl)-3-cyano-4-pyridinyl]-phenyl}-3-(1-piperidinyl)propanamide (0.150 g, 0.270 mmol) in 1,4-dioxane (5 mL) was added 4N HCl in dioxane (2 mL). The mixture was stirred at room temperature for 12 hrs. The resulting precipitate was collected by filtration, washed with ethanol, and dried under reduced pressure to give N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-(1-piperidinyl)propanamide hydrochloride (0.011g, yield 9%).

Molecular weight: 477.998

Mass spectrometry: 442

In vitro activity grade: B

Cellular activity grade: (A954)-B






¹H-NMR(300 MHz, DMSO-d₆): 1.38 - 1.50 (1H, m), 1.71 - 1.84 (5H, m), 2.76 - 3.04 (4H, m), 3.35 - 3.51 (4H, m), 6.90 - 6.98 (2H, m), 7.38 - 7.41 (3H, m), 7.54 (1H, t, J = 7.9 Hz), 7.83 (1H, d, J = 8.2 Hz), 7.95 (1H, s), 8.06 (1H, dd, J = 1.3, 8.2 Hz), 10.42 (1H, brs), 10.64 (1H, brs).






Examples 2-02 to 2-19






In the similar manners as described in Example 2-01 above, the compounds in Examples 2-02 to 2-19 as shown in Table 2 were synthesized.




5

Table 2

EX No	STRUCTURE	mol weight	MS	A549	invitro
2-02		453,889	418	C	B
2-03		453,889	418	C	B
2-04		555,562	442	B	B
2-05		477,998	442	C	B
2-06		520,036	484	C	D


EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
2-07	 ClH	492,025	456	C	C
2-08		656,546	429	B	C
2-09		684,601	457	B	B
2-10		704,031	476	B	B
2-11		661,538	434	B	B

EX No	STRUCTURE	mol weight	MS	A549	invitro
2-12		619,457	392	C	C
2-13		635,911	408	B	A
2-14		687,576	460	B	B
2-15		432,362	319	B	A
2-16		474,400	361	B	A

EX No	STRUCTURE	mol weight	MS	A549	invitro
2-17		442,525	443	C	B
2-18		512,443	476	C	B
2-19		564,832	337	B	D

Example 3-1

5 **N-[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(1-pyrrolidinyl)-phenyl]-3-(1-piperidinyl)propanamide hydrochloride**



To a stirred solution of 2-amino-4-[3-amino-4-(1-pyrrolidinyl)phenyl]-6-[2-(benzyloxyphenyl)]nicotinonitrile (starting compound 3, 0.166 g, 0.360 mmol) in pyridine (3 mL) was added 3-(1-piperidinyl)propanoyl chloride hydrochloride (0.153 g, 0.719 mmol) at room temperature and the stirring was continued for 3 hrs. The reaction mixture was extracted with ethyl acetate and water. The separated organic phase was washed with brine, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The residue was suspended in ethyl acetate and ethanol, and then the precipitate was collected by filtration, washed with ethanol, and dried under reduced pressure to give N-[5-[2-amino-6-(2-benzyloxyphenyl)-3-cyano-4-pyridinyl]-2-(1-pyrrolidinyl)phenyl]-3-(1-piperidinyl)propanamide as a white solid (0.070 g, yield 32%).

A mixture of N-[5-[2-amino-6-(2-benzyloxyphenyl)-3-cyano-4-pyridinyl]-2-(1-pyrrolidinyl)phenyl]-3-(1-piperidinyl)propanamide (0.140 g, 0.233 mmol), 10%Pd-C (0.150 g), ethyl acetate, and acetic acid (2.000 mL) was stirred at room temperature under a hydrogen atmosphere for 12 hrs. The reaction mixture was filtered on Celite Pad and the filtrate was concentrated under reduced pressure. The residue was dissolved in THF (3 mL) and 4N HCl in 1,4-dioxane (0.5 mL) was added to the solution. The resulting yellow solid was collected by filtration, washed with THF, and dried under reduced pressure to give N-[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(1-pyrrolidinyl)phenyl]-3-(1-piperidinyl)propanamide hydrochloride (0.110 g, yield 86%).

Molecular weight: 547.105

Mass spectrometry: 511

Melting point: 152

In vitro activity grade: B

Cellular activity grade: (A954)-B






^1H -NMR(300 MHz, DMSO- d_6): 1.35 - 1.40 (1H, m), 1.67 - 1.80 (6H, m), 1.92 (4H, s), 2.89 - 2.98 (4H, m), 3.29 - 3.57 (8H, m), 3.58 - 3.60 (1H, m), 6.87 - 6.95 (2H, m), 7.02 (1H, d, $J = 7.9$ Hz), 7.30 - 7.37 (3H, m), 7.53 - 7.56 (2H, m), 7.98 (2H, d, $J = 7.2$ Hz), 9.85 (1H, s), 10.45 (1H, brs).

Examples 3-02 to 3-17

In the similar manners as described in Example 3-01 above, the compounds in Examples 3-02 to 3-17 as shown in Table 3 were synthesized.

Table 3

EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
3-02		685,588	458	B	A
3-03		684,601	457	B	A
3-04		670,574	443	B	A
3-05		688,589	461	B	B
3-06		686,573	459	B	B


EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
3-07		644,535	417	B	A
3-08		712,655	485	B	A
3-09		712,655	485	B	C
3-10		752,720	525	B	C
3-11		742,681	515	B	B

EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
3-12		768,720	541	B	B
3-13		740,709	513	B	C
3-14		753,708	526	B	A
3-15		762,715	535	B	C
3-16		823,678	596	B	A

EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
3-17		849,717	622	B	A

Example 4-1

N¹-[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(dimethylamino)-phenyl]-N²-(cyclopropylmethyl)glycinamide hydrochloride



To a cooled (0°C), stirred solution of 2-amino-4-[3-amino-4-(dimethylamino)-phenyl]-6-{2-[(4-methoxybenzyl)-oxy]phenyl}nicotinonitrile (starting compound 4, 0.500 g, 1.724 mmol) in THF(7 mL) under an argon atmosphere was added chloroacetyl chloride (0.121 g, 1.074 mmol). The mixture was stirred at 0°C for 15 minutes and then partitioned between ethyl acetate and saturated aqueous NaHCO₃. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was suspended in ethyl acetate and ethanol. The resulting solid was collected by filtration, washed with ethanol, and dried under reduced pressure to give N-[5-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)oxy]-phenyl}-4-pyridinyl)-2-(dimethylamino)phenyl]-2-chloroacetamide as a yellow solid. (0.410 g, yield 70%)

- 68 -

To a stirred solution of N-[5-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)oxy]phenyl}-4-pyridinyl)-2-(dimethylamino)phenyl]-2-chloroacetamide (0.400 g, 0.738 mmol) in DMF (5 mL) was added aminomethylcyclopropane (0.192 mL, 2.214 mmol). The mixture was stirred at 60°C for 2 hrs. After cooled to room temperature, the mixture was extracted with ethyl acetate and water. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. Purification was carried out by column chromatography on silica gel (chloroform: methanol = 100:2, hexane:ethyl acetate=1:2-1:3-1:5, 2 times) to give N¹-[5-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)oxy]phenyl}-4-pyridinyl)-2-(dimethylamino)phenyl]-N²-(cyclopropylmethyl)-glycinamide as a yellow oil (0.130 g, yield 30%).

To a suspension of N¹-[5-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)oxy]phenyl}-4-pyridinyl)-2-(dimethylamino)-phenyl]-N²-(cyclopropylmethyl)glycinamide (0.130 g, 0.448 mmol) in anisole (1 mL) and water (1 mL) was added trifluoroacetic acid (5 mL). The mixture was stirred at room temperature for 20 hrs. The reaction mixture was diluted with toluene and concentrated under reduced pressure. The residue was suspended in hexane and the precipitate was collected by filtration. The solid obtained was dissolved in THF and 4N HCl in 1,4-dioxane was added to the solution. The resulting solid was collected by filtration, washed with THF and 1,4-dioxane, and dried under reduced pressure to give N¹-[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(dimethylamino)phenyl]-N²-(cyclopropylmethyl)glycinamide hydrochloride as a yellow solid (0.085 g, yield 77%).

Molecular weight: 493.013

Mass spectrometry: 457

In vitro activity grade: B






Cellular activity grade: (A954)-B






¹H-NMR(300 MHz, DMSO-d₆): 0.35 - 0.40 (2H, m), 0.57 - 0.63 (2H, m), 1.05 - 1.08 (1H, m), 2.80 (6H, s), 2.87 - 2.91 (2H, m), 4.66 - 4.68 (2H, m), 6.87 - 6.94 (2H, m), 7.33 - 7.40 (4H, m), 7.52 - 7.55 (1H, m), 7.98 (1H, d, J = 7.2 Hz), 8.09 (1H, s), 9.12 (1H, brs), 10.07 (1H, brs).






Examples 4-02 to 4-39

In the similar manners as described in Example 4-01 above, the compounds in Examples 4-02 to 4-39 as shown in Table 4 were synthesized.






5 **Table 4**






EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
4-02		670,574	443	B	B
4-03		636,593	523	B	C
4-04		738,693	511	B	B
4-05		584,560	471	C	C
4-06		684,601	457	B	B

EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
4-07		656,546	429	B	B
4-08		700,600	473	B	B
4-09		818,736	577	B	C
4-10		684,601	457	B	B
4-11		760,699	533	B	C






EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
4-12		698,628	471	B	B
4-13		714,627	487	B	B
4-14		525,492	412	B	B
4-15		609,654	496	B	B
4-16		726,682	499	B	B

- 72 -






EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
4-17		655,559	428	B	B
4-18		641,532	414	B	A
4-19		629,521	402	B	B
4-20		645,520	418	C	A
4-21		655,559	428	B	B

EX N	MOLSTRUCTURE	mol weight	MS	A549	invitro
4-22		615,494	388	B	B
4-23		641,532	414	B	B
4-24		645,520	418	C	B
4-25		679,965	452	C	A
4-26		741,650	514	C	B




- 74 -


EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
4-27		741,650	514	B	C
4-28		507,529	486	C	C
4-29		507,529	486	C	B
4-30		484,389	448	C	B
4-31		488,377	452	C	A

- 75 -

EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
4-32		715,612	488	B	C
4-33		713,640	486	C	D
4-34		711,624	484	B	D
4-35		725,651	498	C	D
4-36		521,067	485	B	B

- 76 -

EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
4-37		825,651	598	B	A
4-38		821,662	594	B	A
4-39		388,473	389		C

Example 5-1**Sodium 3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]benzoate**

5

A mixture of 3-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)oxy]phenyl}-4-pyridinyl)benzoic acid (starting compound 5, 0.16 g, 0.36 mmol), trifluoroacetic acid

- 77 -

(3.0 mL), anisole (0.50 mL), and water (0.50 mL) was stirred at room temperature overnight. The reaction mixture was diluted with toluene and concentrated under reduced pressure. The residue was dissolved in THF and then crystallized with hexane. The resulting precipitate was collected by filtration and washed with
5 hexane, and then dried under reduced pressure to give 2-amino-6-(2-hydroxyphenyl)-4-(3-hydroxycarbonylphenyl)nicotinonitrile (0.12 g, yield 74%).

2-amino-6-(2-hydroxyphenyl)-4-(3-hydroxycarbonyl-phenyl)nicotinonitrile (0.02 g, 0.045 mmol) was dissolved in 4N NaOH solution (2 mL), and the resulting solution
10 was purified by HPLC (ODS reverse phase column, 10% CH₃CN/H₂O - 90% CH₃CN/H₂O) to give Sodium 3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]benzoate as a pale yellow powder (0.015 g, 95%).

Molecular weight: 353.316

Mass spectrometry: 332

15 Melting point: >270

In vitro activity grade: C

Cellular activity grade: (A954)-C





¹H-NMR(300 MHz, DMSO-d₆): 6.85 - 6.93 (2H, m), 7.31 - 7.56 (5H, m), 7.58 (1H, d, J = 3.0 Hz), 7.99 - 8.06 (2H, m), 8.10 (1H, s), 13.40 (1H, br s).


20

Examples 5-02 to 5-05

In the similar manners as described in Example 5-01 above, the compounds in Examples 5-02 to 5-05 as shown in Table 5 were synthesized.

5 Table 5

EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
5-02		445,358	332	C	B
5-03		353,316	332	C	B
5-04		445,358	332	C	C
5-05		353,316	332	C	B

Example 6-1**3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-N-[2-(1-piperidiny)-ethyl]benzamide trifluoroacetate**

- 5 To a cold (0°C) mixture of 3-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)oxy]-phenyl}-4-pyridinyl)benzoic acid (starting compound 5, 1.35g, 3.00 mmol), N-(2-aminoethyl)piperidine (0.420g, 3.30 mmol), and 1-hydroxybenzotriazole (0.490g, 3.60 mmol) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.69 g, 3.60 mmol) with stirring. The mixture was allowed to warm to
- 10 room temperature and stirred overnight. The reaction mixture was concentrated under reduced pressure. The residue was dissolved in ethyl acetate and partitioned between ethyl acetate and water. The separated organic phase was washed with brine, dried over MgSO₄, filtered and concentrated under reduced pressure. The obtained solid was triturated with ethyl ether and dried under reduced pressure to
- 15 give 2-(1-piperidiny)ethyl 3-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)oxy]-phenyl}-4-pyridinyl)benzoate (0.98 g, yield 58%).

A mixture of 2-(1-piperidiny)ethyl 3-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)-oxy]phenyl}-4-pyridinyl)-benzoate (0.14 g, 0.25 mmol), trifluoroacetic acid

20 (3.00 mL), anisole (0.50 mL) and water (0.50 mL) was stirred at room temperature overnight. The reaction mixture was diluted with toluene and concentrated under reduced pressure. The residue was purified by HPLC (ODS reverse phase column, 10% CH₃CN/H₂O - 90% CH₃CN/H₂O) to give 3-[2-amino-3-cyano-6-(2-hydroxy-

phenyl)-4-pyridinyl]-N-[2-(1-piperidinyl)ethyl]benzamide trifluoroacetate as a pale yellow solid (0.061 g, yield 44%).

Molecular weight: 555.562

Mass spectrometry: 442

5 Melting point: 131 dec

In vitro activity grade: C



Cellular activity grade: (A954)-B


¹H-NMR(300 MHz, DMSO-d₆): 1.36 - 1.86 (6H, m), 2.95 (2H, q, J = 10.5 Hz), 3.26 - 3.28 (2H, m), 3.56 (2H, d, J = 12.4 Hz), 3.66 (2H, J = 6.6 Hz), 6.88 - 6.95 (2H, m),
 10 7.01 (1H, t, J = 7.91 Hz), 7.45 (1H, s), 7.53 (2H, s), 7.70 (1H, t, J = 7.9 Hz), 7.88 (1H, d, J = 7.54 Hz), 8.05 (2H, t, J = 7.0 Hz), 8.12 (1H, s), 8.84 (1H, t, J = 5.7 Hz), 9.02 (1H, br_s), 13.31 (1H, s).

Examples 6-02 to 6-03

15 In the similar manners as described in Example 6-01 above, compounds in Examples 6-02 and 6-03 as shown in Table 6 were synthesized.

Table 6

EX No	MOLSTRUCTURE	mol weight	MS	A549	invitro
6-02		555,562	442	C	B
6-03		555,562	442	B	A

Example 7-1**Sodium 2-amino-4-(3-aminophenyl)-6-(2-hydroxyphenyl)nicotinate**

A mixture of tert-butyl 2-amino-4-(3-aminophenyl)-6-(2-hydroxyphenyl)nicotinate
5 (starting compound 6, 0.025 g, 0.066 mmol) and trifluoroacetic acid (1 mL) was
stirred at room temperature for 2 hrs. After the mixture was concentrated under
reduced pressure, the residue was dissolved in acetonitrile (0.5 mL) and then treated
with saturated NaHCO₃ solution (0.7 mL). The resulting mixture was purified by
HPLC (ODS reverse phase column, 10% CH₃CN/H₂O - 90% CH₃CN/H₂O) to give
10 Sodium 2-amino-4-(3-aminophenyl)-6-(2-hydroxyphenyl)nicotinate as a pale yellow
solid (0.020 g, yield 88%).

Molecular weight: 343.320

Mass spectrometry: 322

Melting point: 140 dec


15 In vitro activity grade: C

Cellular activity grade: (A954)-D

¹H-NMR(300 MHz, DMSO-d₆): 4.94 (2H, s), 6.50 (1H, dd, J = 1.1, 7.9 Hz), 6.63
(1H, d, J = 7.5 Hz), 6.68 (1H, br), 6.73 (2H, s), 6.77 - 6.83 (2H, m), 6.95 (1H, d, J =
7.9 Hz), 6.98 (1H, s), 7.19 (1H, dt, J = 1.5, 8.3 Hz), 7.81 (1H, dd, J = 1.1, 7.9 Hz),
20 14.64 (1H, s).

Example 7-2

Sodium 5-({3-[2-amino-3-(aminocarbonyl)-6-(2-hydroxyphenyl)-4-pyridinyl]-phenyl}amino)-4-hydroxy-5-oxopentanoate



- 5 To a cold (0°C) solution of tert-butyl 2-amino-4-(3-aminophenyl)-6-(2-hydroxyphenyl)nicotinate (starting compound 6, 0.626 g, 1.659 mmol) in THF (7 mL) including pyridine (0.148 mL, 1.824 mmol) was added a solution of 5-oxotetrahydro-2-furancarbonyl chloride (0.271 g, 1.824 mmol) in THF (3 mL). After 1 hr., the mixture was allowed to warm to room temperature and the stirring was continued for
- 10 2 hrs. The mixture was partitioned between ethyl acetate and water. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography on silica-gel (hexane: ethyl acetate, 1:4 - 1:19) to give tert-butyl 2-amino-6-(2-hydroxyphenyl)-4-(3-{{(5-oxotetrahydro-2-furanyl)carbonyl}amino}-phenyl)-nicotinate as a
- 15 pale yellow foam (0.677 g, yield 83%).


- A mixture of tert-butyl 2-amino-6-(2-hydroxyphenyl)-4-(3-{{(5-oxotetrahydro-2-furanyl)carbonyl}amino}-phenyl)nicotinate (0.025 g, 0.051 mmol) in trifluoroacetic acid (1 mL) was stirred at room temperature for 2 hrs. After the mixture was concentrated under reduced pressure, the residue was dissolved in acetonitrile (0.6 mL) and then treated with saturated NaHCO₃ solution (0.2 mL). The resulting mixture was
- 20 purified by HPLC (ODS reverse phase column, 10% CH₃CN/H₂O - 90% CH₃CN/H₂O) to give sodium 2-amino-6-(2-hydroxyphenyl)-4-(3-{{(5-oxotetrahydro-

2-furanyl)carbonyl]amino}phenyl)nicotinate as a pale yellow solid (0.009 g, yield 39%).

- 5 To a cold (0°C) mixture of 2-amino-6-(2-hydroxyphenyl)-4-(3-{{(5-oxotetrahydro-2-furanyl)carbonyl]-amino}phenyl)nicotinic acid (0.070 g, 0.15 mmol), ammonium chloride (0.016 g, 0.30 mmol), 1-hydroxybenzotriazole hydrate (0.032 g, 0.24 mmol) in DMF (2 mL) was added 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (0.034 g, 0.18 mmol) followed by triethylamine (0.042 mL, 0.30 mmol). After 1 hr., the mixture was allowed to warm to room temperature and
- 10 the stirring was continued overnight. The resulting mixture was diluted with water and extracted with ethyl acetate. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by HPLC (ODS reverse phase column, 50% CH₃CN/H₂O - 90% CH₃CN/H₂O) to give a carboxamide analog of the starting material. The product was
- 15 dissolved in acetonitrile (0.7 mL) and then treated with 1N NaOH solution (0.6 mL). The resulting mixture was purified by HPLC (ODS reverse phase column, 10% CH₃CN/H₂O - 90% CH₃CN/H₂O) to give Sodium 5-({3-[2-amino-3-(amino-carbonyl)-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}amino)-4-hydroxy-5-oxopentanoate as a yellow solid (0.005 g, yield 7%).
- 20 Molecular weight: 472.437
Mass spectrometry: 451
Melting point: >260
In vitro activity grade: C
Cellular activity grade: (A954)-C
- 25 ¹H-NMR(300 MHz, DMSO-d₆): 1.72 - 1.96 (2H, m), 2.11 - 2.20 (2H, m), 3.99 (1H, d, J = 6.8 Hz), 6.46 (2H, br), 6.82 (2H, br), 7.17 (1H, d, J = 7.8 Hz), 7.18 (4H, br), 7.34 (1H, t, J = 7.8 Hz), 7.84 (1H, s), 7.87 (1H, d, J = 8.0 Hz), 7.95 (1H, dd, J = 1.3, 8.0 Hz), 9.75 (1H, s), 10.65 (1H, s), 13.91 (1H, s).

Example 7-3

N-{3-[2-amino-3-(hydroxymethyl)-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-(1-piperidinyl)propanamide



- 5 To a cold (0°C) suspension of lithium aluminum hydride (0.077 g, 1.62 mmol) in THF (3 mL) under an argon atmosphere was added dropwise a solution of tert-butyl 2-amino-4-(3-aminophenyl)-6-(2-hydroxyphenyl)nicotinate (0.353 g, 0.935 mmol) in THF (2 mL) with stirring. After 30 minutes, the mixture was allowed to warm to room temperature, and the stirring was continued at room temperature for 2hrs. and
10 at 50°C overnight. After cooled to room temperature, the reaction mixture was quenched with water and extracted with ethyl acetate. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by recrystallization from methanol to give 2-[6-amino-4-(3-aminophenyl)-5-(hydroxymethyl)-2-pyridinyl]phenol as a pale yellow
15 solid (0.133 g, yield 45%).

- To a cold (0°C) solution of 2-[6-amino-4-(3-aminophenyl)-5-(hydroxymethyl)-2-pyridinyl]phenol (0.100 g, 0.325 mmol) in THF (3 mL) including pyridine (0.028 mL, 0.34 mmol) was added 3-chloropropionyl chloride (0.043 g, 0.34 mmol).
20 After being stirred for 30 minutes, the mixture was allowed to warm to room temperature and the stirring was continued for 2 hrs. The resulting mixture was diluted with water and extracted with ethyl acetate. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was crystallized with ethyl ether. The resulting solid was

collected by filtration, washed with ethyl ether, and dried under reduced pressure to give N-{3-[2-amino-3-(hydroxymethyl)-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-chloropropanamide as a pale yellow solid (0.072 g, yield 56%).

5 To a solution of N-{3-[2-amino-3-(hydroxymethyl)-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-chloropropanamide (0.065 g, 0.16 mmol) and sodium iodide (0.007 g, 0.05 mmol) in acetonitrile (5 mL) was added piperidine (0.16 mL, 1.63 mmol), and the mixture was stirred at 75°C overnight. After cooled to room temperature, the resulting mixture was diluted with water and extracted with ethyl acetate. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica-gel (chloroform: methanol, 85:15) to give N-{3-[2-amino-3-(hydroxymethyl)-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-(1-piperidinyl)propanamide as a white foam (0.055 g, yield 75%).

15 Molecular weight: 446.554

Mass spectrometry: 447

Melting point: 133dec

In vitro activity grade: B


Cellular activity grade: (A954)-B

20 ¹H-NMR(300 MHz, DMSO-d₆): 1.36 - 1.55 (6H, m), 2.39 - 2.65 (8H, m), 4.34 (2H, d, J = 4.9 Hz), 5.08 (1H, t, J = 4.9 Hz), 6.49 (2H, s), 6.78 (1H, dt, J = 1.1, 8.3 Hz), 6.85 (1H, dd, J = 1.5, 8.67 Hz), 7.10 (1H, s), 7.14 (1H, d, J = 7.9 Hz), 7.23 (1H, dt, J = 1.5, 8.7 Hz), 7.40 (1H, t, J = 7.9 Hz), 7.61 (1H, s), 7.66 (1H, d, J = 8.3 Hz), 7.86 (1H, dd, J = 1.5, 8.3 Hz), 10.28 (1H, s), 14.22 (1H, s).

25

Example 8-1

2-[6-amino-4-[4-(ethylamino)-3-hydroxyphenyl]-5-(hydroxymethyl)-2-pyridinyl]-3-(cyclopropylmethoxy)phenol hydrochloride



5 A mixture of 1-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}ethanone (starting compound 1-A' 2.00 g, 6.13 mmol), 3-hydroxy-4-nitrobenzaldehyde (2.05 g, 12.26 mmol), tert-butyl cyanoacetate (1.73 g, 12.26 mmol), ammonium acetate (1.42 g, 18.38 mmol) and 1,2-dimethoxyethane (2.0 mL) was placed in a sealed tube and was stirred at 100°C for 8 hrs. After being cooled to room
10 temperature, the mixture was concentrated under reduced pressure, and the residue was partitioned between ethyl acetate and water. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel (hexane: ethyl acetate, 1:1) to give tert-butyl 2-amino-6-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}-4-(3-hydroxy-4-nitrophenyl)nicotinate. (2.32 g, 62%);
15 LC-MS (m/z= 614, M+1)

A solution of tert-butyl 2-amino-6-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}-4-(3-hydroxy-4-nitrophenyl)nicotinate (2.32 g, 3.78 mmol) in ethyl
20 acetate (15.0 mL) and THF (15.0 mL) was hydrogenated at 1 atm in the presence of palladium on charcoal (10%, 0.10 g) overnight. The resulting mixture was filtered on Celite and washed with ethyl acetate and THF. The combined filtrate was concentrated under reduced pressure to give tert-butyl 2-amino-4-(4-amino-3-hy-

droxyphenyl)-6-[2-[(4-methoxybenzyl)oxy]-6-(2-methylbutoxy)phenyl]nicotinate.
(2.21 g, 100%); LC-MS (m/z = 584, $M+1$)

5 To a solution of tert-butyl 2-amino-4-(4-amino-3-hydroxyphenyl)-6-[2-[(4-methoxybenzyl)oxy]-6-(2-methylbutoxy)phenyl]nicotinate (2.46 g, 4.21 mmol) was added acetic anhydride (0.44 mL, 4.63 mmol). The mixture was stirred at room temperature for overnight. The mixture was diluted with ethyl acetate and washed with saturated aqueous NaHCO_3 and brine. The organic phase was dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give tert-butyl 4-[4-(acetylamino)-3-hydroxyphenyl]-2-amino-6-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}nicotinate. (2.65 g, 100%); LC-MS (M/z = 626, $M+1$)

15 To a cold (0 °C) solution of tert-butyl 4-[4-(acetylamino)-3-hydroxyphenyl]-2-amino-6-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}nicotinate (1.00 g, 1.60 mmol) in THF (15.0 mL) under argon atmosphere was added a solution of sodium bis(2-methoxyethoxy)aluminum hydride (3.7 N in toluene, 1.25 mL, 6.39 mmol) in THF (2 mL) dropwise. After being stirred for 5 hrs., a solution of sodium bis(2-methoxyethoxy)aluminum hydride (3.7 N in toluene, 0.833 mL, 4.26 mmol) in THF (1 mL) was added to the mixture at 0°C, then the mixture was
20 allowed to warm to room temperature, and the stirring was continued overnight. The mixture was quenched with ethyl acetate and poured into saturated aqueous sodium potassium tartarate. The extracted organic phase was washed with brine, dried over Na_2SO_4 , filtered and concentrated under reduced pressure to give 5-[2-amino-6-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}-3-(hydroxymethyl)-4-pyridinyl]-2-(ethylamino)phenol.; LC-MS (m/z = 542 $M+1$)
25

To a solution of 5-[2-amino-6-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}-3-(hydroxymethyl)-4-pyridinyl]-2-(ethylamino)phenol (0.013 g, 0.023 mmol) in 1,4-dioxane (0.5 mL) was added a solution of HCl in 1,4-dioxane
30 (4N, 1.0 mL). After being stirred overnight, the mixture was diluted with diethyl ether. The resulting precipitate was collected by filtration under argon atmosphere,

washed with Et₂O, and dried under reduced pressure to give 2-[6-amino-4-[4-(ethylamino)-3-hydroxyphenyl]-5-(hydroxymethyl)-2-pyridinyl]-3-(cyclopropylmethoxy)phenol. (0.008 g, 76%); LC-MS (m/z = 422 M+1)
Molecular weight: 457.961

5 Mass spectrometry: 422

Melting point: 232dec


In vitro activity grade:B

Cellular activity grade: (A954)-

¹H-NMR(500 MHz, DMSO-d₆): 0.26 (2H, m), 0.47 (2H,m), 1.13 (1H, m), 1.20 (3H, t, J = 7.3 Hz), 3.19 (2H, m), 3.57 (1H, s), 3.86 (2H, m), 4.51 (2H, s), 6.64 (2H, m),
10 6.82 (1H, s), 6.94 (2H, m), 7.28 (2H, m), 10.3 (1H, br), 13.3 (1H, br).

Example 8-2

7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl-5-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one hydrochloride
15



To a cold (0 °C) solution of 5-[2-amino-6-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}-3-(hydroxymethyl)-4-pyridinyl]-2-(ethylamino)phenol (0.150 g, 0.28 mmol) in THF (5.0 mL) including triethylamine (0.12 mL, 0.83 mmol) was
20 added triphosgene (0.099 g, 0.33 mmol). After being stirred for 30 minutes, the mixture was allowed to warm to room temperature, and the stirring was continued overnight. The resulting mixture was quenched with water and extracted with ethyl acetate. The separated organic phase was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by

column chromatography on silica gel (dichloromethane: methanol, 9:1) to give 7-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}-5-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one. (0.049 g, 30%); LC-MS (m/z = 594, M+1)

5

To a solution of 7-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}-5-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one (0.036 g, 0.065 mmol) in 1,4-dioxane (1.0 mL) was added a solution of HCl in 1,4-dioxane (4N, 1.0 mL). After being stirred overnight, the mixture was diluted with diethyl ether. The resulting precipitate was collected by filtration under argon atmosphere, washed with Et₂O, and dried under reduced pressure to give 7-[2-(cyclopropylmethoxy)-6-(hydroxy)phenyl]-5-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one. (0.025 g, 80%); LC-MS (m/z = 436, M+1)

10

15 Molecular weight: 509.951

Mass spectrometry: 474

Melting point: 151

In vitro activity grade: C


Cellular activity grade: (A954)-

20

¹H-NMR(500 MHz, DMSO-d₆): 0.29 (2H, m), 0.49 (2H, m), 1.20 (1H, m), 1.30 (3H, t, J = 7.3 Hz), 3.87 (2H, d, J = 6.5 Hz), 3.92 (2H, m), 5.43 (2H, s), 6.55 (2H, d, J = 8.2 Hz), 6.92 (0.5 H, d, J = 8.5 Hz), 7.19 (1H, t, J = 8.2 Hz), 7.33 (2H, m), 7.49 (2H, m), 7.97 (1H, s).

Example 8-3

N-{4-[2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-3-(hydroxymethyl)-4-pyridinyl]-2-hydroxyphenyl}acetamide hydrochloride



- 5 To a cold (0 °C) solution of tert-butyl 4-[4-(acetylamino)-3-hydroxyphenyl]-2-amino-6-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}nicotinate (1.65 g, 2.64 mmol) in THF (25.0 mL) under argon atmosphere was added a solution of sodium bis(2-methoxyethoxy)aluminum hydride (3.7 N in toluene, 4.12 mL, 21.1 mmol) in THF (3 mL) dropwise. After being stirred for 30 minutes, the mixture
- 10 was quenched with ethyl acetate and poured into saturated aqueous sodium potassium tartarate. The extracted organic phase was washed with brine, dried over Na₂SO₄, filtered and concentrated under reduced pressure. The residue was purified by column chromatography on silica gel (dichloromethane: methanol, 19:1 – 9:1) to give N-{4-[2-amino-6-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}-3-(hydroxymethyl)-4-pyridinyl]-2-hydroxyphenyl}acetamide (0.48 g, 33%); LC-MS
- 15 (m/z = 556, M+1).

- To a solution of N-{4-[2-amino-6-{2-(cyclopropylmethoxy)-6-[(4-methoxybenzyl)oxy]phenyl}-3-(hydroxymethyl)-4-pyridinyl]-2-hydroxyphenyl}acetamide (0.013 g, 0.023 mmol) in 1,4-dioxane (0.5 mL) was added a solution of HCl in 1,4-dioxane (4N, 1.0 mL). After being stirred overnight, the mixture was diluted with diethyl ether. The resulting precipitate was collected by filtration under argon atmosphere, washed with Et₂O, and dried under reduced pressure to give of N-{4-[2-amino-6-[2-
- 20

(cyclopropylmethoxy)-6-hydroxyphenyl]-3-(hydroxymethyl)-4-pyridinyl]-2-hydroxyphenyl} acetamide. (0.025 g, 80%); LC-MS (m/z = 436, M+1)

Molecular weight: 471.945

Mass spectrometry: 436

5 Melting point: 270 dec

In vitro activity grade: A



Cellular activity grade: (A954)-

¹H-NMR(500 MHz, DMSO-d₆): 0.27 (2H, m), 0.47 (2H, m), 1.14 (1H, m), 2.14 (3H, s), 3.86 (2H, d, J = 7.0 Hz), 4.47 (2H, d, J = 11 Hz), 6.64 (2H, dd, J = 8.2, 25 Hz),
10 6.84 (1H, m), 6.94 (1H, m), 7.03 (1H, s), 7.28 (1H, m), 7.56 (1H, br), 7.94 (1H, br), 9.46 (1H, s), 10.2 (1H, br), 13.5 (1H, br).

Examples 8-04 to 8-05


15 In the similar manners as described in Example 8-01 to 8-03 above, the compounds in Examples 8-04 to 8-05 as shown in Table 8 were synthesized.

Table 8

EX No	STRUCTURE	mol weight	MS	A549	invitro
8-04		365,392	366	A	A
8-05		401,853		B	A

Example 9

N-{4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-[2-(1-piperidinyl)-ethoxy]phenyl}acetamide ditrifluoroacetate



- 5 A mixture of 2-[(4-methoxybenzyl)oxy]acetophenone, 3-hydroxy-4-nitrobenzaldehyde, malononitrile, ammonium acetate and toluene was stirred under reflux for 3 hrs. The usual work-up and column chromatography gave 2-amino-4-(3-hydroxy-4-nitrophenyl)-6-{2-[(4-methoxybenzyl)oxy]-phenyl}nicotinonitrile.
- 10 A mixture of 2-amino-4-(3-hydroxy-4-nitrophenyl)-6-{2-[(4-methoxybenzyl)oxy]-phenyl}nicotinonitrile, cesium carbonate, potassium iodide and DMF was stirred at 80°C overnight. The usual work-up and column chromatography gave 2-amino-6-{2-[(4-methoxybenzyl)oxy]phenyl}-4-{4-nitro-3-[2-(1-piperidinyl)ethoxy]-phenyl}nicotinonitrile.
- 15 A mixture of 2-amino-6-{2-[(4-methoxybenzyl)-oxy]phenyl}-4-{4-nitro-3-[2-(1-piperidinyl)ethoxy]phenyl}-nicotinonitrile, SnCl₂ and DMF was stirred at room temperature overnight. The usual work-up and column chromatography gave 2-amino-4-{4-amino-3-[2-(1-piperidinyl)ethoxy]phenyl}-6-{2-[(4-methoxybenzyl)-oxy]-phenyl}nicotinonitrile.
- 20

5 A mixture of 2-amino-4-{4-amino-3-[2-(1-piperidinyloxy)]phenyl}-6-{2-[(4-methoxybenzyl)oxy]-phenyl}nicotinonitrile, acetyl chloride, pyridine and CH₂Cl₂ was stirred at 0°C for 1 hr. and at room temperature for 2 hrs. The usual work-up and column chromatography gave N-{4-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)-oxy]phenyl}-4-pyridinyl)-2-[2-(1-piperidinyloxy)]phenyl}acetamide.

10 A mixture of N-{4-(2-amino-3-cyano-6-{2-[(4-methoxybenzyl)oxy]phenyl}-4-pyridinyl)-2-[2-(1-piperidinyloxy)]phenyl}acetamide and trifluoroacetic acid was stirred at room temperature for 3 hrs. Evaporation of trifluoroacetic acid gave N-{4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-[2-(1-piperidinyloxy)]phenyl}acetamide ditrifluoroacetate.


Molecular weight: 699.612

Mass spectrometry: 472

In vitro activity grade: B

15 Cellular activity grade: (A954)-B


Comparative examples



20 6-(2-Hydroxyphenyl)-4-(R''-phenyl)-3-cyano-2-aminopyridines (wherein R'' is nitro or dimethylamino) disclosed in Mannna et al., (Eur. J. Med. Chem. 34 (1999) 245-254) were synthesized according to the methods disclosed in the document. The effects of the synthesized compounds were examined by the in vitro assay method and cellular assay method disclosed herein. These compounds did not show any IKK-beta inhibitory activity and cytokine inhibitory activity.

CLAIMS

1. A 4-aryl pyridine derivative of the formula (I):



5 wherein

X is CH or N;

10 R¹ is hydrogen, hydroxy, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy-carbonyl, nitro, amino, mono or di (C₁₋₆ alkyl)amino, phenylsulfonyl-amino, -NHR¹¹ or -O-(CH₂)_n-R¹²,

 wherein

15 R¹¹ is phenyl substituted C₁₋₆ alkyl, C₁₋₆ alkanoyl or C₁₋₆alkyl-sulfonyl,

n represents an integer selected from 0 to 6, and

20 R¹² is C₂₋₆ alkenyl, benzoyl, mono or di phenyl, mono or di (C₁₋₆ alkyl)amino, C₁₋₆ alkanoyl, C₁₋₆ alkoxy-carbonyl, or a 3 to 10 membered saturated or unsaturated ring having 0 to 3 hetero-atoms selected from the group consisting of S, O and N, and said ring is optionally substituted by hydroxy, nitro, cyano,
25 mono or di halogen, C₁₋₆ alkyl, halogen substituted C₁₋₆ alkyl,

amino, mono or di (C₁₋₆ alkyl)amino, C₁₋₆ alkanoylamino, carbamoyl, C₁₋₆ alkoxy, C₁₋₆ alkoxycarbonyl, or phenyl;

R² is hydrogen, hydroxy, halogen, or C₁₋₆ alkyl;

R³ is hydrogen, hydroxy, halogen, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl substituted C₁₋₆alkyloxy, -N R³¹R³², or a 3 to 6 membered saturated ring having 0 to 3 heteroatoms selected from the group consisting of O and N, and said ring is optionally substituted by R³³;

Wherein

R³¹ is hydrogen or C₁₋₆ alkyl

R³² is hydrogen, C₁₋₆ alkanoyl, or C₁₋₆ alkyl optionally substituted by hydroxy or phenyl,

R³³ is nitro, cyano, C₁₋₆ alkyl optionally substituted by hydroxy or amino, C₁₋₆ alkoxy, hydroxy substituted C₁₋₆ alkyloxy, amino substituted C₁₋₆ alkyloxy, C₁₋₆ alkanoyl, carbamoyl or -NR^{33a}R^{33b}

Wherein

R^{33a} is hydrogen or C₁₋₆ alkyl

R^{33b} is hydrogen, C₁₋₆ alkyl optionally substituted by hydroxy or phenyl, C₁₋₆ alkanoyl, C₁₋₆ alkylsulfonyl, or trifluoroacetyl,

R^4 is hydrogen, hydroxy, carboxy, $-\text{CO}-\text{NHR}^{41}$, amino, C_{1-6} alkyl-sulfonylamino, or $-\text{NH}-\text{COR}^{41}$, C_{1-6} alkyl optionally substituted by R^{42} , C_{1-6} alkoxy, $R^{43}\text{C}_{1-6}$ alkyloxy,

5 wherein

R^{41} is C_{1-6} alkyl optionally substituted by R^{41a} , C_{1-6} alkoxy, oxo-tetrahydrofuryl, oxopyrrolidinyl, $-\text{CH}(\text{OH})R^{41b}$, $-\text{CH}(\text{NH}_2)R^{41c}$, $-\text{NHR}^{41c}$, or piperazino optionally substituted by R^{41d} ,

10 wherein

R^{41a} is carboxy, C_{1-6} alkoxy, $-\text{CH}(\text{NH}_2)\text{carboxy}$, $-\text{NR}^{41a-1}R^{41a-2}$, or a 3 to 10 membered saturated ring having 0 to 3 heteroatoms selected from the group consisting of O and N, and said ring is optionally substituted by carboxy, C_{1-6} alkyl optionally substituted by hydroxy or benzodioxane, C_{3-6} cycloalkyl, C_{1-6} alkanoyl, carboxy, benzyl, C_{1-6} alkoxycarbonyl, or furoyl,

20 wherein

R^{41a-1} is hydrogen or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkyloxy, C_{3-8} cycloalkyl, or piperidino,

25

R^{41a-2} is hydrogen or C_{1-6} alkyl optionally substituted by hydroxy, C_{1-6} alkyloxy or C_{3-6} cycloalkyl, C_{1-6} alkoxy or a 3 to 6 membered saturated ring having 0 to 3 heteroatoms selected from the

30

group consisting of O and N, and said ring is optionally substituted by carboxy, C₁₋₆ alkyl, C₁₋₆ alkanoyl, or C₁₋₆ alkyloxy,

5 R^{41b} is C₁₋₆ alkyl optionally substituted by carboxy or C₁₋₆ alkyloxy, C₁₋₆ alkoxy, or C₁₋₆ alkoxycarbonyl,

10 R^{41c} is carboxy, C₁₋₆ alkyl optionally substituted by carboxy or a 3 to 6 membered saturated ring having 0 to 3 heteroatoms selected from the group consisting of O and N, or

15 R^{41d} is C₁₋₆ alkyl optionally substituted by carboxy or C₁₋₆ alkyloxy, or C₁₋₆ alkoxy

20 R⁴² is C₁₋₆ alkoxy, carboxy, amino, -CH(NH₂)-carboxy or a 5 to 7 membered saturated or unsaturated ring having 0 to 3 heteroatoms selected from the group consisting of O and N, and said ring is optionally substituted by hydroxy, nitro, mono or di halogen, C₁₋₆ alkyl, halogen substituted C₁₋₆ alkyl, amino, mono or di (C₁₋₆ alkyl)amino, or carbamoyl;

25 R⁴³ is carboxy, amino, -CH(NH₂)-carboxy or a 5 to 7 membered saturated or unsaturated ring having 0 to 3 heteroatoms selected from the group consisting of O and N, and said ring is optionally substituted by hydroxy, nitro, mono or di halogen, C₁₋₆ alkyl, halogen substituted C₁₋₆ alkyl, amino, mono or di (C₁₋₆ alkyl)amino, or carbamoyl;

or

30

R³ and R⁴ may form, together with the carbon atoms in the benzene ring, a 4 to 6 membered saturated ring having 0 to 3 heteroatoms selected from the group consisting of O and N, and said ring is optionally substituted by one or more substituents selected from the group consisting of hydroxy, nitro, mono or di halogen, C₁₋₆ alkyl, halogen substituted C₁₋₆ alkyl, oxo, amino, mono or di (C₁₋₆ alkyl)amino, and carbamoyl;

R⁵ is hydrogen, cyano, carboxy, carbamoyl, C₁₋₆ alkyl optionally substituted by hydroxy or carbamoyl, and C₁₋₆ alkoxy carbonyl, and

R⁶ is -NR⁶¹R⁶²,

wherein

R⁶¹ is hydrogen or C₁₋₆ alkyl,

R⁶² is hydrogen, C₁₋₆ alkyl, phenyl, benzyl, C₁₋₆ alkanoyl, or

NR⁶¹R⁶² may form, together with the nitrogen atom to which they are attached, a saturated 5-6 membered ring optionally containing NH or O as other heteroatoms than the adjacent N atom

or

R⁵ and R⁶ may form, together with the carbon atoms in the pyridine ring, a 5 to 7 membered saturated or unsaturated ring having 0 to 3 heteroatoms selected from the group consisting of O, S and N, and said ring optionally having substituents selected from the group consisting of halogen, nitro, cyano, oxo, thioxo, C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy carbonyl, phenyl, C₁₋₆ alkanoyl, amino, C₁₋₆ alkyl-amino, C₁₋₆ alkanoylamino, carbamoyl, C₃₋₈ cycloalkylaminocarbonyl,

C₁₋₆ alkylaminocarbonyl, halogen substituted C₁₋₆ alkylamino-
carbonyl, di (C₁₋₆ alkyl)aminocarbonyl, benzoylamino, phenyl-
sulfonyl, di(C₁₋₆ alkyl)aminoC₁₋₆ alkylaminocarbonyl, hydroindenyl-
aminocarbonyl, diphenylmethylaminocarbonyl, pyrrolidinocarbonyl,
5 C₁₋₆ alkyloxy C₁₋₆ alkyl amino carbonyl, morpholinocarbonyl,
piperazinocarbonyl, phenylC₁₋₆alkylaminocarbonyl, carboxyC₁₋₆ alkyl-
aminocarbonyl, C₃₋₈ cycloalkylC₁₋₆alkylaminocarbonyl, hydroxy
C₁₋₆alkylaminocarbonyl, and methylsulfonylaminocarbonyl

10 or a salt thereof.

2. The compound or a salt thereof as claimed in claim 1,

wherein

15

X is CH or N;

R¹ is hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy or C₃₋₆ cycloalkyl
substituted C₁₋₆ alkyloxy;

20

R² is hydrogen or halogen;

R³ is hydrogen, hydroxy, halogen, C₁₋₆ alkoxy, C₃₋₆ cycloalkyl substituted
C₁₋₆alkyloxy, amino, mono or di (C₁₋₆ alkyl)amino, C₁₋₆ alkanoyl-
25 amino, C₁₋₆ alkyl(hydroxy substituted C₁₋₆ alkyl)amino, C₁₋₆ alkyl-
(benzyl)amino, morpholino, piperidino, or pyrrolidino optionally
substituted by C₁₋₆ alkyl, C₁₋₆ alkyloxy or hydroxy substituted C₁₋₆
alkyl, amino, di(C₁₋₆ alkyl)amino, or trifluoroacetyl amino;

30

R⁴ is hydrogen, hydroxy, carboxy, C₁₋₆ alkyl optionally substituted by
piperazino, C₁₋₆ alkoxy, piperidino substituted C₁₋₆ alkyloxy, amino,

C₁₋₆ alkylsulfonylamino, piperidino C₁₋₆ alkyl- aminocarbonyl, or -NH-COR⁴¹,

wherein

5

R⁴¹ is C₁₋₆ alkyl optionally substituted by R^{41a}, C₁₋₆ alkoxy, C₁₋₆ alkyloxy substituted C₁₋₆ alkyl, oxotetrahydrofuryl, oxopyrrolidinyl, -CH(OH)R^{41b}, -CH(NH₂)R^{41c}, or -NHR^{41c}

10

wherein

15

R^{41a} is C₁₋₆ alkoxy, carboxy, -NHR^{41a-1} (wherein R^{41a-1} is hydrogen, or C₁₋₆ alkyl optionally substituted by hydroxy, C₁₋₆ alkyloxy, C₃₋₈ cycloalkyl, or piperidino), -CH(NH₂) -N(C₁₋₆ alkyl)R^{41a-2} (wherein R^{41a-2} is C₁₋₆ alkyl or C₁₋₆ alkyl substituted pyrrolidinyl), pyrrolidinyl, piperidino optionally substituted by carboxy or C₁₋₆ alkoxycarbonyl, piperidino optionally fused with C₃₋₆ cycloalkyl, or piperazino optionally substituted by C₁₋₆ alkyl, hydroxy substituted C₁₋₆ alkyl, benzodioxane substituted C₁₋₆ alkyl, C₁₋₆ alkanoyl, C₃₋₆ cycloalkyl, benzyl, or furoyl,

20

25

R^{41b} is C₁₋₆ alkyl optionally substituted by carboxy, or C₁₋₆ alkoxycarbonyl,

R^{41c} is C₁₋₆ alkyl optionally substituted by carboxy or piperidino,

or

30

R³ and R⁴ may form, together with the carbon atoms in the benzene ring, a 5 membered saturated ring having 0 to 2 heteroatoms selected from the group consisting of O and N, and said ring is optionally substituted by C₁₋₆ alkyl, or oxo;

R⁵ is hydrogen, carbamoyl, cyano, carboxy, C₁₋₆ alkoxy carbonyl, or hydroxy substituted C₁₋₆ alkyl; and

R⁶ is amino or C₁₋₆ alkanoylamino,

or

R⁵ and R⁶ may form, together with the carbon atoms in the pyridine ring, a 6 membered saturated or unsaturated ring having 0 to 3 heteroatoms selected from the group consisting of O, S and N, and said ring optionally having substituents selected from the group consisting of halogen, nitro, cyano, oxo, thioxo, C₁₋₆ alkyl, C₁₋₆ alkylsulfonyl, C₁₋₆ alkoxy, C₁₋₆ alkoxy carbonyl, phenyl, C₁₋₆ alkanoyl, amino, C₁₋₆ alkylamino, C₁₋₆ alkanoylamino, carbamoyl, C₃₋₈ cycloalkylaminocarbonyl, C₁₋₆ alkylaminocarbonyl, halogen substituted C₁₋₆ alkylaminocarbonyl, and di (C₁₋₆ alkyl)aminocarbonyl

or a salt thereof.

3. The compound or a salt thereof as claimed in claim 1,

wherein

X is CH or N;

R¹ is hydrogen, halogen, C₁₋₆ alkoxy, or cyclopropyl methoxy;

R² is hydrogen;

R³ is hydrogen, hydroxy, halogen, amino, mono or di(C₁₋₆ alkyl)amino, acetamido, C₁₋₆alkoxy, cyclopropyl methoxy, C₁₋₆ alkyl(hydroxy substituted C₁₋₆ alkyl)amino, C₁₋₆ alkyl(benzyl)amino, morpholino, piperidino, or pyrrolidino optionally substituted by C₁₋₆ alkyl, hydroxy substituted C₁₋₆ alkyl, amino, di (C₁₋₆ alkyl)amino, or trifluoroacetyl-amino;

R⁴ is hydrogen, hydroxy, carboxy, amino, C₁₋₆ alkylsulfonylamino, piperazino, C₁₋₆ alkyl substituted piperazino, piperidino substituted C₁₋₆ alkyloxy, piperidino C₁₋₆ alkyl- aminocarbonyl, or -NH-COR⁴¹,

wherein

R⁴¹ is C₁₋₆ alkyl optionally substituted by R^{41a}, C₁₋₆ alkoxy, oxo-tetrahydrofuryl, oxopyrrolidinyl, -CH(OH)R^{41b}, or -CH(NH₂)R^{41c},

wherein

R^{41a} is C₁₋₆ alkoxy, carboxy, -CH(NH₂)-carboxy, -NHR^{41a-1} (wherein R^{41a-1} is hydrogen, C₁₋₆ alkyl optionally substituted by hydroxy, C₃₋₈ cycloalkyl, C₁₋₆ alkoxy, or piperidino), -N(C₁₋₆ alkyl)R^{41a-2} (wherein R^{41a-2} is C₁₋₆ alkyl or C₁₋₆ alkyl substituted pyrrolidinyl), pyrrolidinyl, piperidino optionally substituted by carboxy or C₁₋₆ alkoxycarbonyl, piperidino fused with cyclohexane, or piperazino optionally substituted by C₁₋₆ alkyl, hydroxy substituted C₁₋₆ alkyl, benzodioxane

substituted C₁₋₆ alkyl, benzyl, C₁₋₆ alkanoyl, cyclohexyl, or furoyl,

5 R^{41b} is C₁₋₆ alkyl optionally substituted by carboxy or C₁₋₆ alkoxy carbonyl,

 R^{41c} is C₁₋₆ alkyl optionally substituted by carboxy,
or

10 R³ and R⁴ may form -NR⁴⁰¹-CO-O-(wherein R⁴⁰¹ is hydrogen or C₁₋₆ alkyl);

 R⁵ is hydrogen, carbamoyl, cyano, carboxy, or hydroxymethyl; and

 R⁶ is amino or acetamido

15

or

 R⁵ and R⁶ may form -R⁵⁰-CH₂-NH-, -R⁵⁰-CO-NH-, -R⁵⁰-SO₂-NH-, or
 -R⁵⁰-C(=S)-NH-

20

wherein

 R⁵⁰ is -CHR⁵⁰¹-O-, -CH₂-N R⁵⁰¹-, -CO-NR⁵⁰¹-, (wherein R⁵⁰¹ is
25 hydrogen, C₁₋₆ alkyl, C₁₋₆ alkanoyl, C₁₋₆ alkoxy carbonyl,
 carbamoyl, C₁₋₆ alkylsulfonyl, C₃₋₈ cycloalkylaminocarbonyl,
 C₁₋₆ alkylaminocarbonyl, di (C₁₋₆ alkyl)aminocarbonyl or
 phenyl)

or a salt thereof.

30

4. The compound as claimed in claim 1 selected from the group consisting of the following compounds:

5-({3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl} amino)-4-hydroxy-5-oxopentanoate;

5 N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-5-oxotetrahydro-2-furancarboxamide;

N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}methanesulfonamide;

10 N⁴-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-L-asparagine;

N¹-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-L-asparagine;

N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-(1-piperidinyl)propanamide;

15 5-({4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl} amino)-4-hydroxy-5-oxopentanoate;

4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-N-[2-(1-piperidinyl)ethyl]benzamide;

4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]benzoic acid;

20 5-({5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-chlorophenyl} amino)-4-hydroxy-5-oxopentanoate;

N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-2-[4-(2-furoyl)-1-piperazinyl]acetamide;

25 N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-(4-ethyl-1-piperazinyl)propanamide;

N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-3-octahydro-1(2H)-quinolinylpropanamide;

N¹-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-N²-cyclopentylglycinamide;

30 N¹-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-N²-(cyclopropylmethyl)glycinamide;

- N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^2 -propylglycinamide;
- N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^2 -(3-hydroxypropyl)glycinamide;
- 5 N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^3 -(cyclopropylmethyl)- β -alaninamide;
- N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^2,N^2 -dimethylglycinamide;
- 10 N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}-2-(1-pyrrolidinyl)acetamide;
- N^1 -{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]phenyl}- N^2 -[2-(methyloxy)ethyl]glycinamide;
- N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(3-amino-1-pyrrolidinyl)phenyl]- β -alaninamide;
- 15 N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(1-piperidinyl)phenyl]- β -alaninamide;
- N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(1-pyrrolidinyl)phenyl]- β -alaninamide;
- 20 N^1 -{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-[ethyl(2-hydroxyethyl)amino]phenyl}- β -alaninamide;
- N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(4-morpholinyl)phenyl]- β -alaninamide;
- N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(dimethylamino)phenyl]- β -alaninamide;
- 25 N-{3-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-4-chlorophenyl}-3-(1-piperidinyl)propanamide;
- 2-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]benzoic acid;
- 2-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-N-[2-(1-piperidinyl)ethyl]benzamide;
- 30 N^1 -{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-chlorophenyl}- N^2 -(cyclopropylmethyl)glycinamide;

- N^1 -{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-chlorophenyl}- N^2 -(2-methoxyethyl)glycinamide;
- N^1 -{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-chlorophenyl}- β -alaninamide;
- 5 2-amino-4-(4-amino-3-hydroxyphenyl)-6-(2-hydroxyphenyl)nicotinonitrile;
- N -{4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-hydroxyphenyl}acetamide;
- N -{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-chlorophenyl}-3-(1-piperidinyl)propanamide;
- 10 N^1 -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(dimethylamino)phenyl]- N^2 -(cyclopropylmethyl)glycinamide;
- N -[5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-(dimethylamino)phenyl]-3-(1-piperidinyl)propanamide;
- N^1 -{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-[(2S)-2-(hydroxymethyl)-1-pyrrolidinyl]phenyl}-L-leucinamide;
- 15 N^1 -{5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-[(3S)-3-(dimethylamino)-1-pyrrolidinyl]phenyl}- N^2 -(cyclopropylmethyl)glycinamide;
- N^1 -(5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-{3-[(trifluoroacetyl)amino]-1-pyrrolidinyl}phenyl)-L-leucinamide;
- 20 N -(5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-{3-[(trifluoroacetyl)amino]-1-pyrrolidinyl}phenyl)-3-(1-piperidinyl)propanamide;
- N^1 -(5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-{3-[(trifluoroacetyl)amino]-1-pyrrolidinyl}phenyl)- N^2 -(2-methoxyethyl)glycinamide;
- 25 N^1 -(5-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-{3-[(trifluoroacetyl)amino]-1-pyrrolidinyl}phenyl)- N^2 -(cyclopropylmethyl)glycinamide;
- 2-amino-6-(2-hydroxyphenyl)-4-(3-hydroxyphenyl)nicotinonitrile;
- N -{4-[2-amino-3-cyano-6-(2-hydroxyphenyl)-4-pyridinyl]-2-[2-(1-piperidinyl)ethoxy]phenyl}acetamide;
- 30 N -{4-[2-amino-3-(hydroxymethyl)-6-(2-hydroxyphenyl)-4-pyridinyl]-2-hydroxyphenyl}acetamide;

2-[6-amino-4-[4-(ethylamino)-3-hydroxyphenyl]-5-(hydroxymethyl)-2-pyridinyl]-3-(cyclopropylmethoxy)phenol;

N-{4-[2-amino-6-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-3-(hydroxymethyl)-4-pyridinyl]-2-hydroxyphenyl} acetamide;

5 7-[2-(cyclopropylmethoxy)-6-hydroxyphenyl]-5-(3-ethyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-1,4-dihydro-2H-pyrido[2,3-d][1,3]oxazin-2-one;

5. A pharmaceutical composition comprising the compound or a salt thereof as claimed in claim 1 as an active ingredient.

10

6. A pharmaceutical composition comprising the compound or a salt thereof as claimed in claim 1 together with one or more pharmaceutically acceptable excipients.

15

7. An IkB kinase β inhibitor comprising the compound or a salt thereof as claimed in claim 1 as an active ingredient.

8. An anti-inflammatory agent comprising the compound or a salt thereof as claimed in claim 1 as an active ingredient.

20

9. The anti-inflammatory agent as claimed in claim 6, wherein said agent is used to treat or prevent a disease selected from the group consisting of asthma; allergic rhinitis; atopic dermatitis; hives; conjunctivitis; vernal catarrh; chronic arthrorheumatism; systemic lupus erythematosus; psoriasis; diabrotic colitis; systemic inflammatory response syndrome (SIRS); sepsis; polymyositis; dermatomyositis (DM); polyarthritis nodosa (PN); mixed connective tissue disease (MCTD); Sjogren's syndrome; and gout.

25

10. An immunosuppressant comprising the compound or a salt thereof as claimed in claim 1 as an active agent.

30

11. An agent to treat ischemia comprising the compound or a salt thereof as claimed in claim 1 as an active agent.
- 5 12. An anti-tumor agent comprising the compound or a salt thereof as claimed in claim 1 as an active agent.
13. Use of compounds of the general formula (I) according to any one of Claims 1 to 4 for the production of medicaments.
- 10 14. Use according to Claim 13, in which the medicaments are for the control of inflammatory disorders.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/13338

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D213/85 A61K31/44 A61P29/00 C07D405/12 C07D401/12
 C07D401/10 C07D213/73 C07D213/80 C07D213/82 C07D498/04
 A61K31/4545 A61K31/496 A61K31/5377

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EPO-Internal, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	DATABASE CHEMCATS 'Online! Chemical Abstracts Service, Columbus, Ohio, US, retrieved from STN; XP002197384 order number 4732-BAS0727649 & "Ambinter: Screening collection" 31 May 2001 (2001-05-31), AMBINTER, 75016 PARIS, FRANCE ---	1-3
P,X	DATABASE CHEMCATS 'Online! Chemical Abstracts Service, Columbus, Ohio, US, retrieved from STN; XP002197385 order number: BAS 0727649 & "AsInEx Compound Collection" 10 May 2001 (2001-05-10), ASINEX, 123182 MOSCOW, RUSSIA --- -/-	1-3

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *S* document member of the same patent family

Date of the actual completion of the international search

26 April 2002

Date of mailing of the international search report

22/05/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Kollmannsberger, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/13338

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>DATABASE CHEMCATS 'Online! Chemical Abstracts Service, Columbus, Ohio, US, retrieved from STN; XP002197386 order numbers: TRG08000#05404-D; TRG08000#09403-D; TRG08000#00603-D; TRG08000#13126-D; TRG08000#13135-D; TRG08000#13131-D; TRG08000#13121-D; TRG08000#13124-D; TRG08000#13122-D; TRG08000#01963-D & "Chem.Folio" , LION BIOSCIENCE AG , 69027 HEIDELBERG, GERMANY</p>	1-3
P,X	<p>KUMAR, NEERAJ ET AL: "Synthesis of some 2-thioxopyrido'2,3-d!pyrimidine ribofuranosides and their antimicrobial activity" PHOSPHORUS, SULFUR AND SILICON AND THE RELATED ELEMENTS (2001), 175, 217-225 , XP001070068 page 223; example IIF</p>	1-3
X	<p>ANKHIWALA, M. D.: "Synthesis and biological studies of some 2-amino-3-cyano-4-aryl-6- (2'-hydroxy-4'-n-butoxy-5'-H/nitrophenyl)p yridines" J. INDIAN CHEM. SOC. (1992), 69(3), 166-7, XP002197382 page 167; examples 2J,,2K</p>	1-3
X	<p>MANNA, FEDELE ET AL: "Anti-inflammatory, analgesic and antipyretic 4,6-disubstituted 3-cyano-2-aminopyridines" EUR. J. MED. CHEM. (1999), 34(3), 245-254, XP004168450 cited in the application page 247; examples 3A-3Q page 250; table V</p>	1-14
X	<p>MANNA, F. ET AL: "Anti-inflammatory, analgesic and antipyretic 4,6-disubstituted 3-cyanopyridin-2-ones and 3-cyano-2-aminopyridines" EUR. J. MED. CHEM. (1992), 27(6), 627-32 , XP002188651 page 628; example 3A page 630; table III</p>	1-14
A	<p>LEWIS A J; MANNING A M: "New targets for anti-inflammatory drugs" CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 3, 1999, pages 489-494, XP002197383 the whole document</p>	1-14

-/-

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 01/13338

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	<p>WO 02 24651 A (BAYER AG ;MURATA TOSHIKI (JP)) 28 March 2002 (2002-03-28) the whole document</p>	1-14

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 01/13338

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 0224651	A	28-03-2002	WO	0224679 A1	28-03-2002
			WO	0224651 A1	28-03-2002
			WO	0224693 A1	28-03-2002
<hr/>					

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/044153 A1

(51) International Patent Classification⁷: C07D 213/85,
A61K 31/44, A61P 29/00, C07D 405/12, 401/12, 401/10,
213/73, 213/80, 213/82, 498/04, A61K 31/4545, 31/496,
31/5377

(21) International Application Number: PCT/EP01/13338

(22) International Filing Date:
19 November 2001 (19.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2000-366708 1 December 2000 (01.12.2000) JP

(71) Applicant (for all designated States except US): BAYER
AKTIENGESELLSCHAFT [DE/DE]; 51368 Lev-
erkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MURATA, Toshiki
[JP/JP]; 1-3-501, Nakano-cho, Ikoma-shi, Nara 630-0267
(JP). SAKAKIBARA, Sachiko [JP/JP]; 544-1A-1,
Sanjo-cho, Nara-shi, Nara 630-8244 (JP). YOSHINO,
Takashi [JP/JP]; 1-1-17-101, Saidaiji-Nogami-cho,
Nara-shi, Nara 631-0833 (JP). IKEGAMI, Yuka
[JP/JP]; 942, Fushimi Godo Shukusha, Nishibu-
gyo-cho, Fushimi-ku, Kyoto 612-8104 (JP). MA-
SUDA, Tsutomu [JP/JP]; 3-15-6-6A, Jingu, Nara-shi,
Nara 631-0804 (JP). SHIMADA, Mitsuyuki [JP/DE];
Mozartstr. 31, 40667 Meerbusch (DE). SHINTANI,
Takuya [JP/JP]; 4-24-1, Seikadai, Seika-cho, So-
raku-gun, Kyoto 619-0238 (JP). SHIMAZAKI, Makoto

[JP/JP]; 5-5-3-1, Kunimidai, Kizu-cho, Soraku-gun,
Kyoto 619-0216 (JP). LOWINGER, Timothy, B.
[CA/JP]; 5-7-203, Chitose-cho, Nishinomiya-shi, Hyogo
662-0046 (JP). ZIEGELBAUER, Karl, B. [DE/DE]; Gut-
tentag-Loben-Str. 21, 42781 Haan (DE). FUCHIKAMI,
Kinji [JP/JP]; 7-1-8-A103, Umemidai, Kizu-cho, So-
raku-gun, Kyoto 619-0215 (JP). UMEDA, Masaomi
[JP/JP]; 2-840-156, Sahodai, Nara-shi, Nara 630-8105 (JP).
KOMURA, Hiroshi [JP/JP]; 2-1-8, Saidaiji-Shiba-machi,
Nara-shi, Nara 631-0825 (JP). YOSHIDA, Nagahiro
[JP/JP]; 5-18-15, Saganakadai, Kizu-cho, Soraku-gun,
Kyoto 619-0223 (JP).

(74) Common Representative: BAYER AKTIENGE-
SELLSCHAFT; 51368 Leverkusen (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI,
SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU,
ZA, ZW.


(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:

— with international search report

[Continued on next page]

(54) Title: 4-6-DIPHENYL PYRIDINE DERIVATIVES AS ANTIINFLAMMATORY AGENTS



(57) Abstract: 4-aryl pyrimidine compounds of general formula and salts thereof; wherein X is CH or N; R¹ is hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, etc.; R² is hydrogen, halogen, etc.; R³ is hydrogen, hydroxy, halogen, amino, etc.; R⁴ is hydroxy, amino, carboxy, etc. or R³ and R⁴ together form a ring; R⁵ is hydrogen, carbamoyl, cyano, carboxy, C₁₋₁₆ alkoxy, carbonyl, etc. and R⁶ is amino or C₁₋₁₆ alkanoylamino or R⁵ and R⁶ together form a ring. The compounds (I) or the salts thereof have an excellent anti-inflammatory activity and act as inhibitors of IKK- β and thus inhibit nuclear factor kappa B (NF- κ B).

WO 02/044153 A1



— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

(15) Information about Correction:

see PCT Gazette No. 29/2002 of 18 July 2002, Section II

(48) Date of publication of this corrected version:

18 July 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/044153 A1(51) International Patent Classification⁷: C07D 213/85,
A61K 31/44, A61P 29/00, C07D 405/12, 401/12, 401/10,
213/73, 213/80, 213/82, 498/04, A61K 31/4545, 31/496,
31/5377

(21) International Application Number: PCT/EP01/13338

(22) International Filing Date:
19 November 2001 (19.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2000-366708 1 December 2000 (01.12.2000) JP(71) Applicant (for all designated States except US): BAYER
AKTIENGESSELLSCHAFT [DE/DE]; 51368 Lev-
erkusen (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): MURATA, Toshiki
[JP/JP]; 1-3-501, Nakano-cho, Ikoma-shi, Nara 630-0267
(JP). SAKAKIBARA, Sachiko [JP/JP]; 544-1A-1,
Sanjo-cho, Nara-shi, Nara 630-8244 (JP). YOSHINO,
Takashi [JP/JP]; 1-1-17-101, Saidaiji-Nogami-cho,
Nara-shi, Nara 631-0833 (JP). IKEGAMI, Yuka
[JP/JP]; 942, Fushimi Godo Shukusha, Nishibu-
gyo-cho, Fushimi-ku, Kyoto 612-8104 (JP). MA-
SUDA, Tsutomu [JP/JP]; 3-15-6-6A, Jingu, Nara-shi,
Nara 631-0804 (JP). SHIMADA, Mitsuyuki [JP/DE];
Mozartstr. 31, 40667 Meerbusch (DE). SHINTANI,
Takuya [JP/JP]; 4-24-1, Seikadai, Seika-cho, So-
raku-gun, Kyoto 619-0238 (JP). SHIMAZAKI, Makoto
[JP/JP]; 5-5-3-1, Kunimidai, Kizu-cho, Soraku-gun,Kyoto 619-0216 (JP). LOWINGER, Timothy, B.
[CA/JP]; 5-7-203, Chitose-cho, Nishinomiya-shi, Hyogo
662-0046 (JP). ZIEGELBAUER, Karl, B. [DE/DE]; Gut-
tentag-Loben-Str. 21, 42781 Haan (DE). FUCHIKAMI,
Kinji [JP/JP]; 7-1-8-A103, Umemidai, Kizu-cho, So-
raku-gun, Kyoto 619-0215 (JP). UMEDA, Masaomi
[JP/JP]; 2-840-156, Sahodai, Nara-shi, Nara 630-8105 (JP).
KOMURA, Hiroshi [JP/JP]; 2-1-8, Saidaiji-Shiba-machi,
Nara-shi, Nara 631-0825 (JP). YOSHIDA, Nagahiro
[JP/JP]; 5-18-15, Saganakadai, Kizu-cho, Soraku-gun,
Kyoto 619-0223 (JP).(74) Common Representative: BAYER AKTIENGE-
SELLSCHAFT; 51368 Leverkusen (DE).(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,
SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZM, ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,
NE, SN, TD, TG).

Published:


— with international search report

(48) Date of publication of this corrected version:

28 November 2002

[Continued on next page]

(54) Title: 4-6-DIPHENYL PYRIDINE DERIVATIVES AS ANTIINFLAMMATORY AGENTS

(57) Abstract: 4-aryl pyrimidine compounds of general formula and salts thereof; wherein X is CH or N; R¹ is hydrogen, halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, etc.; R² is hydrogen, halogen, etc.; R³ is hydrogen, hydroxy, halogen, amino, etc.; R⁴ is hydroxy, amino, carboxy, etc. or R³ and R⁴ together form a ring; R⁵ is hydrogen, carbamoyl, cyano, carboxy, C₁₋₆ alkoxy, carbonyl, etc. and R⁶ is amino or C₁₋₆ alkanoylamino or R⁵ and R⁶ together form a ring. The compounds (I) or the salts thereof have an excellent anti-inflammatory activity and act as inhibitors of IKK-β and thus inhibit nuclear factor kappa B (NF-κB).

WO 02/044153 A1



(15) Information about Corrections:

see PCT Gazette No. 48/2002 of 28 November 2002, Section II

Previous Correction:

see PCT Gazette No. 29/2002 of 18 July 2002, Section II

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Serial No., 10/613,482
Filing Date: 07/03/2003
Stefanie Flohr, et al
DEAV2002/0045 US NP